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Role of Astrocyte-Derived Extracellular Vesicles in
Neuroinflammation Mediated by Drug Abuse
Ke Liao, Ph.D.
University of Nebraska Medical Center, 2019
Supervisor: Shilpa Buch, Ph.D.
Neuronal damage and neuroinflammation is a hallmark feature of HIV-associated
neurological disorders (HANDs). Opioids abuse accelerates the incidence and
progression of HAND; however, the mechanisms underlying the potentiation of
neuropathogenesis by these drugs remain elusive. Extracellular vesicles (EVs) are
essential conduits in HIV and drug abuse-mediated synaptodendritic injury and
neuroinflammation. Findings from our group have demonstrated that astrocyte-derived EV
(ADEV)-miRNA-29b mediates HIV Tat and morphine-induced neuronal injury, thus
underscoring the importance of such interactions in NeuroHIV.
Besides, HIV Tat and morphine-mediated synaptodendritic injury via ADEVs, we
are also interested in whether ADEVs contributes to neuroinflammation. Microglia are
critical players in neuroinflammation. Morphine could regulate microglial function;
However, the role of ADEVs in morphine-mediated dysregulation of microglia remains
elusive. Additionally, drugs of abuse such as opioids can result in a breach of the bloodbrain barrier (BBB), ultimately leading to enhanced monocyte transmigration and ensuing
neuroinflammation. Recently studies provide compelling evidence that pericyte loss on the
microvessels results in increased extravasation of peripheral immune cells. Mechanism(s)
by which pericytes contribute to morphine-mediated neuroinflammation, however, remains
less understood.
The overarching goal of this thesis is to explore another undefined role of the
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morphine-mediated release of EV-miRNAs in regulating microglial and pericyte function(s),
which, in turn, leading to neuroinflammation. We found that 1) morphine stimulated ADEVs
can be taken up by microglial cells, leading, in turn, to impaired microglial phagocytosis
via the TLR7-NF-kB -lincRNA-Cox2 axis and intranasal delivery of lincRNA-Cox2 siRNA
restored microglial phagocytic activity of morphine-administered mice; 2) exposure of
astrocytes in culture to morphine resulted in increased expression and secretion of miR138 in the ADEVs which in turn, were taken up by the microglia, resulting in microglial
activation, via binding to endosomal TLR7; 3) exposure of astrocytes to morphine resulted
in induction and release the of miR-23a in the ADEVs, which, taken up by pericytes,
leading to loss of pericyte thus lead to influx of monocyte (Figure 1).
Our findings could have clinical ramifications in the future for developing EV-loaded
RNA-based therapeutics that aimed at managing neuroinflammation-associated cognitive
disorders in the context of chronic morphine abuse and HIV-opiate comorbidities.
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CHAPTER I
INTRODUCTION
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1. ROLE OF EXTRACELLULAR VESICLE IN NEUROINFLAMMATION
1.1 Overview
Cellular cross-talk has been demonstrated to involve in majority pathological
conditions of the central nervous system (CNS) disorders. Although various mechanisms
have been implicated as players capable of mediating the pathogenesis of the disease,
neuroinflammation has recently emerged as the critical hallmark features of various
neurological disorders. In consideration of this light, extracellular vesicles (EVs) and their
associated cargos-mediated neuroinflammation may accelerate or contribute to the
pathogenesis of neurological disorders is recently gaining momentum. EVs are
membrane-bound nanovesicles released from most cell types that initially thought to be
waste bags containing 'junk' cellular debris. Recently, emerging findings have proven that
EVs are no longer waste bags. Instead, EVs have an essential role as cargo-carrying
vesicles mediating cellular communication that contribute pathogenesis of neurological
disease through their ability to distribute disease-causing factors among CNS cells. This
review focuses on examining the role of EVs in the pathogenesis of various
neurodegenerative disorders and their potential as the carriers of therapeutic agents for
treating neuroinflammation and biomarkers for diagnosing various neurological diseases.
1.2 EV isolation and Cargo
Appropriate isolation and purification methods are importantly required for the
accurate functional characterization of EV cargo (Jabalee et al., 2018). Currently,
differential ultracentrifugation has been well accepted as the most popular and classic
method of EV isolation(Gardiner et al., 2016). Differential ultracentrifugation goes through
the step with low-speed centrifugation (1,000 g) for dead cell removal, mid-speed
centrifugation (10,000 g) for debris removal, then followed by pelleting of EVs at highspeed (100,000 g). This method is low-cost with high throughput that makes it an ideal
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means of EV isolation well accepted all over the world. However, this method cannot rule
out contamination with non-vesicular proteins, especially when isolating EVs from material
such as serum and brain tissue(Webber and Clayton, 2013). For this challenge, many
other methods come up with better purity or quantity of EVs, such as a combination of
differential ultracentrifugation with density gradient centrifugation, size-exclusion
chromatography, immunoaffinity capture, and precipitation-based methods. However, all
the alternative methods have their advantages and disadvantages (Ramirez et al., 2018).
Briefly, size-exclusion chromatography provides excellent purity, but it will give low EVs
concentration with sample dilution effect, and thus, this method requires re-concentration.
In contrast, precipitation methods seem to give high yield but fail to have a high purity of
EVs. Immunoaffinity capture can be used to isolate specific subtype of EVs sharing a
specific characteristic marker, such as isolating CD63+ EVs. However, low antibody
affinity and specificity could be the limitation of this method (Kanwar et al., 2014). In
addition, there is remaining unknown of whether markers capable of distinguishing among
exosomes, ectosomes, apoptotic bodies, and other EVs. Since these techniques for EVs
isolation based on different characteristics such as size, density, specific surface markers
and so on, those isolated EVs may enrich different subpopulations, which, in turn,
potentially leads to misleading results (Mateescu et al., 2017). For additional detail of EVs
studies, we refer the reader to the guidelines of minimal information for studies of
extracellular vesicles 2018 (Thery et al., 2018). After EVs isolation, the next important step
is to profile the various types of EV cargo and their functional impacts in the
neuroinflammation.
In terms of EVs cargo, microRNAs (miRs) are most well studied. The miRs are a
group of small, non-coding RNA molecules with about 22 nucleotides in length, which can
regulate the translation and degradation of various mRNA targets (Carthew and
Sontheimer, 2009). This functional activity makes miRs as the powerful controller of cell
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phenotype. Recently, emerging evidence demonstrated that EV-miRs could be taken up
by recipient cells, thereby enabling miRs to participate in intercellular communication
within CNS. For example, Prada et al. have demonstrated inflammatory microglial could
release and transfer miR-146a-5p to the hippocampal neurons via EVs. The EV-miR146a-5p could decrease the expression of Syt1 and Nlg1 in neurons, which, in turn, leads
to reduced dendritic spines (Prada et al., 2018). Microglia could be recipient cells as well.
There are several inflammatory-related miRs such as MiR-124, miR-21, and let-7 found in
neuron-derived EVs, taken up by the microglia, regulating neuroinflammation (Morton et
al., 2018), (Pinto et al., 2017), (Simeoli et al., 2017), (Harrison et al., 2016). Our previous
study also demonstrated that EV-miR-9 released from HIV-Tat-exposed astrocyte could
be taken up by microglial, which, in turn, leads to microglial migration via regulating
expression of PTEN (Yang et al., 2018).
Long intergenic noncoding RNAs (lincRNAs), defined as being >200 nucleotides
in length, are regulatory RNA molecules (Briggs et al., 2015). LincRNAs play essential
roles in the controlling of many cellular processes via regulating gene transcription, mRNA
stability, protein translation, chromatin organization, and formation of regulatory
complexes (Kretz et al., 2013), (Ulitsky and Bartel, 2013), (Noh et al., 2018), (Huarte,
2013), (Sun et al., 2018a), (Leone and Santoro, 2016). Numerous lincRNAs have been
found in EVs such as MALAT1 (Patel et al., 2019), HOTAIR (Wang et al., 2019), H19 (Ma
et al., 2017), lincRNA-p21 (Gezer et al., 2014), GAS5 (Chen et al., 2017), (Gezer et al.,
2014), TUG1 (Barbagallo et al., 2018), TUC339 (Li et al., 2018) HULC (Cao et al., 2019b),
UCA1(Barbagallo et al., 2018). A growing body of studies has demonstrated those
lincRNAs can regulate the inflammatory response. For example, Cao et al. have shown
that lincRNA Malat1 acts as a sponge of miR-181c-50p to result in the up-regulation of
HMGB1, which, in turn, leads to inflammation in stroke (Cao et al., 2019a). Besides,
LincRNA-H19 (Obaid et al., 2018), lincRNA-p21 (Ye et al., 2018), GAS5 (Yue et al., 2018),
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lincRNA UCA1 and HULC (Chen et al., 2019) are all studied to show positively regulate
the inflammatory response. However, TUG1 and TUC339 have demonstrated the activity
of anti-inflammation (Zhang et al., 2018), (Li et al., 2018). Given that, it strongly indicates
that EV-lincRNAs could be a potential player in mediating neuroinflammation.
Circular RNAs (circRNAs) are known as a novel type of endogenous noncoding
RNA highly abundant in the mammalian brain (Rybak-Wolf et al., 2015) that are garnering
increased attention in recent times. These non-coding RNAs generated by back splicing
of a covalent bond linking the 3' and 5' ends and have been shown to act as natural
sponges for miRs, which can repress the activity of the corresponding miRs, thus
regulating the target genes. Intriguingly, the study of Li et al. has identified 1215 circRNAs
in the human serum exosomes (Li et al., 2015). They strongly suggest the exosomal
circRNAs could be the promising biomarkers for the disease diagnosis. In addition,
according to the findings from Lasda et al. suggested that EVs could be a novel
mechanism for clearance of circRNA (Lasda and Parker, 2016). Furthermore, several
studies have demonstrated circRNAs could regulate the inflammatory response, such as
Circ-Atp9b and hsa_circ_0005105 could promote the induction of proinflammatory
cytokines IL-6 and IL-8 through targeting miR-138-5p and miR-26a (Zhou et al., 2018b),
(Wu et al., 2017). In summary, these data indicate that EV-circRNAs are promising
regulators of and potential therapeutic targets for the neuroinflammation-related disease.
Besides non-coding RNAs, mRNAs (Protein-coding RNA) have been found in the
EVs. And those EV-resident mRNAs can be translated to generate functional proteins in
the recipient cells (Tannous et al., 2005). In addition, there is a study used microarrays to
find 13,000 mRNAs in MC/9 cell-derived EVs. Intriguingly, there are 270 mRNAs only
detected in EVs other than in the cells. For our interesting, the work done by Mitsuhashi
et al. (Mitsuhashi et al., 2013) has demonstrated that macrophage-derived EVs isolated
from aging subjects contained higher levels of EV mRNAs of IL6, TNF, and IL12. This find
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indicates that EV-cytokine mRNAs could be a novel mechanism for the spreading of
neuroinflammation among different cell types induced by aging.
In addition to their nucleic acid contents, EVs are also loaded with various proteins
and lipids. In consideration of the EV biogenesis, for every subtype of EVs are shed by
the plasma membrane. All the EVs contained the plasma membrane proteins and lipids.
While exosomes are released by the fusion of multivesicular body (MVBs) with the plasma
membrane, there are several unique membrane proteins (exosome markers) to these
vesicles compared to the cell surface. For examples, exosomes harbor tetraspanins (CD9,
CD63, CD81) from the endosomal origin, proteins functioning for membrane transport and
fusion (Rab5, Rab proteins, Annexins and SNAP), proteins required for MVB formation
(TSG101 and Alix ), proteins associated with cell-targeting/adhesion (Integrins, ICAM-1,
CD31). The exosomes also contain various cytoskeletal proteins (actin, tubulin, profilin,
cofilin, and so on). Additionally, a variety of metabolic enzymes (GAPDH, pyruvate kinase,
ATPase, and so on) were found in the exosomes. Intriguingly, antigen-presenting cellsderived exosomes also express proteins (MHCI/II and HLA-G) on the membrane for the
antigen presentation. Furthermore, in the context of pathological conditions, the EVs are
implicated in spreading pathological proteins among the cells. For example, HIV proteins
(HIV Tat (Rahimian and He, 2016), Nef, (Khan et al., 2016), and gp120 (Env) (Arakelyan
et al., 2017)) were detected in EVs of HIV+ infected cells
1.3 Cargo sorting into EVs

Although EVs carry active biological cargo (proteins and nucleic acids) has been
well studied over the last three decades. The mechanism of the proteins and nucleic acids
sorting into EVs is remaining elusive. Few known selective mechanisms have been
documented. One of the most well-studied machinery called Endosomal Sorting Complex
Required for Transport (ESCRT) is a pathway responsible for the sorting of proteins into
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EVs. There are five distinct ESCRTs, known as ESCRT-0, -I, -II, -III and IV (Schuh and
Audhya, 2014). The first three ESCRTs majorly located in the cytoplasm, playing a role in
recognizing and packaging proteins into the EVs. And the ESCRT-III and -IV function
specifically on membranes involved in membrane fission and EVs release (McCullough et
al., 2018) In this machinery, post-translational modifications(PTMs) play an essential role
in labeling protein to control the state of proteins switching between active or inactive,
ensuring selective proteins can be sorted into the EVs. The PTMs majorly include
ubiquitination, phosphorylation, sumoylation, myristoylation, and glycosylation that involve
the sorting of proteins into the EVs. For example, ESCRT-0 interacts with
phosphatidylinositol 3-phosphate (PI3P) that triggers the membrane recruitment process,
followed by recruiting ESCRT-I. Then, ESCRT-I binds to ubiquitinated cargo. Next,
ESCRT-II recruits ESCRT-I, PI3P, and cargo via interacting with the Glue domain of
Vps36. Meanwhile, the ESCRT-II subunit Vps25 serves as a nucleation point for the
assembly of the filamentous ESCRT-III complex (Schmidt and Teis, 2012). Finally, the
assembled Vps4 enzyme (ESCRT-IV) in complex with an ESCRT-III substrate promoting
membrane fission reactions, which sequesters cargo into the EVs for releasing.
On the evaluation of RNA cargo in EVs, one of the surprising aspects of EV RNA
content is somewhat distinct profiles when compared to the RNA content of the cells from
where they are derived ((Skog et al., 2008), (Pigati et al., 2010), (Guduric-Fuchs et al.,
2012). In consideration of specific RNAs (especially miRNAs) are enriched in EVs, thus
implicating there are selective loading mechanisms by which sort of active RNAs into the
EVs (Baglio et al., 2015). The most well-studied mechanism is the RNA-binding proteinsmediated sorting of miRs into EVs. For example, the study from Carolina et al. has
demonstrated

that

one

RNA-biding

protein

named

heterogeneous

nuclear

ribonucleoprotein A2B1 (hnRNPA2B1) could recognize and bind to GGAG motif in the 3’
portion of miR that results in selectively sorting of these miRs into the EVs. And
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sumoylation of hnRNPA2B1 controls the binding activity to miRs (Villarroya-Beltri et al.,
2013). There is another group, Matthew et al. have demonstrated HEK293-derived
exosome contained Y-box protein 1, and this RNA binding protein involves sorting of miR223 into the exosomes. Furthermore, human ELAV protein HuR, another RNA binding
protein, has been demonstrated to play a role in sorting miRs into the EVs. According to
the study done by Kamalika et al., they have shown that HuR could replace miR from the
RNA-induced silencing complex (RISC or miRNP). Subsequently, the ubiquitination of
HuR results in disassociating HuR from miRs on multivesicular bodies (MVBs) and thus
facilitates the release of HuR‐disassociated miRs via EVs (Mukherjee et al., 2016).
Additionally, Argonaute 2 (AGO2) is an essential RNA binding protein for miR activity
(Tarallo et al., 2017). It will bind to mature miRs to form the RISC that find targeting-mRNA,
activating RNase and cleaving the RNA to achieve inhibition of its target expression.
Intriguingly, Andrew et al. have detected AGO2 in the exosomes and play a role in the
sorting of miRs into the EVs. They found an oncogenic gene KRAS that induces
phosphorylation of AGO2 S387, which, in turn, leads to suppression of itself and AGO2coupled miRs secretion in EVs (McKenzie et al., 2016). Besides RNA binding proteinsmediated sorting of miRs into the EVs, PTM of miRs also contributes to selective loading
mechanisms by which sort of active miRs into EVs. For instance, Danijela et al. have
demonstrated that the nucleotide addition of miRs affects its relative abundance of miRs
in cells v.s EVs. Intriguingly, they found 3′-end adenylation of miRNA promotes its location
in the cells while 3′-end uridylation of miR in the EVs (Koppers-Lalic et al., 2014).
1.4 Neuroinflammatory disorders and EVs

Increasing evidence suggests that cell-derived EVs as vectors of inflammatory and
immune mediators to be important in one or more neuropathologic syndromes. Those
mediators could be cytokines, pathological proteins (Aβ peptides, tau protein, α-synuclein,
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and so on) or miRNAs, which are selectively sorted into EVs and distributed among
recipient cells that leads to dysfunction of targeting cells.
1.5 Alzheimer’s disease and EVs
Alzheimer’s disease (AD), a most common neurodegenerative disease, is
characterized by memory disturbance and cognitive impairment. Worldwide, it is reported
that 50 million people were living with AD in 2018. Predictably, there will be more than 150
to 152 million AD patients by 2050 (Patterson, 2018). Extracellular deposition of betaamyloid (Aβ) peptide (Murphy and LeVine, 2010), intracellular accumulation of
hyperphosphorylated tau protein in the neurofibrillary tangles (Brion, 1998), cholinergic
dysfunction (Ferreira-Vieira et al., 2016) and neuroinflammation (Zhang and Jiang, 2015)
are the major salient pathological features of AD. Although there are several prescription
drugs available to treat people diagnosed with AD that focus on slowing down the
symptoms of the disease, none to cure or eradicate the disease (Folch et al., 2016).
Therefore, think about addressing underlying disease processes should be looked beyond
treating symptoms. Recently, emerging evidence suggests EVs could play a critical role
in the pathogenesis of AD via spreading the EV-contained pathogenic AD proteins. For
instance, Hirohide Asai et al. demonstrated that microglia spread tau from the entorhinal
cortex to the dentate gyrus via exosomes and inhibition of exosome synthesis significantly
suppressed the propagation of tau in vitro and in vivo (Asai et al., 2015). Besides, neuronderived exosome contained human Tau has been shown toxic to the recipient neurons in
vivo (Winston et al., 2019). Furthermore, the exosome isolated from cultured neurons or
human cerebrospinal fluid (CSF) from AD or control subjects indeed contains Tau. In
addition, there are a lot of studies demonstrate exosomes could be considered as carriers
of Alzheimer's Amyloid-ß. In 2002, observation of electron microscopy showed
accumulated Aß located within neuronal endosomes such as MVBs (precursors of
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exosomes)(PMID: 12414533 ). Furthermore, Rajendran et al. reported a highly enriched
expression of Alix (exosomal marker) is around human amyloid plaques (Rajendran et al.,
2006). In addition, the exosome isolated from the CSF of AD patients found to contain Aß
(Joshi et al., 2014). Those findings indicate that exosome-contained Aß could contribute
to the formation of plaque.
1.6 Prion diseases and EVs
Prion diseases, known as a spectrum of transmissible lethal neurodegenerative
disorders, are characterized by cognitive impairment, motor dysfunction, spongiosis,
gliosis, and cerebral aggregation of insoluble PRNP (prion protein) (Bagyinszky et al.,
2018). In prion disease, PRNP has two forms of PRNPC (a native form) and PRNPSC (a
pathogenic form, prone to aggregation). The PRNPC has at least two functions: on the
one hand, it is the substrate for aggregating the pathological structure of prion proteins
(PRNPSC). On the other hand, it could bind to Aβ oligomers that associated with the
initiation of AD. Intriguingly, there is mounting evidence to show the cellular prion proteins
both PRNPC and PRNPSC highly expressed on the exosome from a PrP-expressing
neuronal cell line. And the exosome PRNPSC still can infect the uninfected recipient cells
(neuronal and non-neuronal cells). In line with these studies, Cervenakova et al. showed
that blood-derived exosome (isolated from prion-infected mice) contained infectivity. And
injected those exosomes to the non-infection mice, it can successfully result in the
transmission of the prion disease (Cervenakova et al., 2016). Further study demonstrated
that PRNPC and PRNPSC could induce the release of exosomes. Given those findings
indicate that exosome plays an essential role in the spreading of the prion disease.
1.7 Parkinson’s disease and EVs
Parkinson’s disease (PD), one of the most common slow-progressive
neurodegenerative disorders, is characterized by a broad spectrum of progressive motor
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symptoms (bradykinesia, postural inability, rigidity, and tremor) and non-motor symptoms
(constipation, depression, sleep, cognitive dysfunction). A well-accepted pathologic trait
of PD is an aggregation of misfolded α-synuclein that is triggering dopaminergic
neurotoxicity. In PD, several studies have demonstrated that EVs-contained α-synuclein
can be released from neuronal or non-neuronal cells (Danzer et al., 2012; Shi et al., 2014;
Stuendl et al., 2016). Intriguingly, EVs-contained α-synuclein oligomers are more prone to
be taken up by recipient cells compared with EVs-free α-synuclein oligomers. Further
study demonstrated that EVs-contained α-synuclein oligomers showed a greater effect on
caspase activation, which, in turn, leads to more cytotoxicity (Danzer et al., 2012). EVscontained α-synuclein could release from the neuron and take-up by neurons (neuron-toneuron), which contributes to the spreading of α-synuclein among the neurons that results
in direct neuronal damage. In addition, neuron-to-glia or glia-to-glia could lead to glial
activation that promotes neuroinflammation (Russo et al., 2012). The possible indirect
mechanism by which EV-contained α-synuclein-mediated exacerbated neuroinflammation
that contributes to neuronal dysfunctions and the progression of the disease.
1.8 HIV associated-neurocognitive disorders (HAND) and EVs

Using of combined antiretroviral therapy (cART) has been shown a dramatic
increase in the life spans of individuals infected with HIV-1. In fact, in 2015, there has been
an almost 45% decrease in the number of people dying with HIV compared with those in
2005. HIV continues to be a major global public health concern with an estimated 37.9
million currently living with HIV (organization, 2019). Despite the virus suppression and
increased longevity of those on cART, the brain often remains an organ with persistent
low-level virus replication – leading to the persistence of HAND in almost 30-50% of
infected individuals(Heaton et al., 2010). Additionally, it is well established that cART does
on impact production of the early viral protein HIV Tat, which has been implicated in

12
cytotoxicity and ensuing neuroinflammation(Chivero et al., 2017; Rice, 2017; Thangaraj et
al., 2018). Adding further complexity to HAND is the invariable comorbidity of drug abuse
in approximately one-third of all AIDS cases in the USA. Several studies have
demonstrated drug abuse such as morphine during infection, could further promote the
incidence and progression of HIV-associated neuro-dysfunction(Bokhari et al., 2011).
However, there is a gap in knowledge regarding the mechanism(s) by which morphine
potentiates HAND. Our previous study has demonstrated astrocyte-derived EV-miR-29b
mediates HIV and opiate-induced neuronal injury via suppression of the neuroprotective
protein platelet-derived growth factor (PDGF)-B expression in the neuron. Further study,
exposure of astrocytes to HIV Tat resulted in increased expression and release of several
miRs in the EV cargo, specifically the brain-enriched miR-7, which upon uptake by the
hippocampal neurons, resulted in loss of inhibitory synapses via miR-7-mediated
downregulation of its target neuroligin 2 (NLGN2) -a crucial known regulator of inhibitory
synapses (Hu et al., 2019). In addition, HIV Tat-mediated induction and release of miR-9
in ADEVs, which upon uptake by the microglia, resulted in enhanced migration of
microglial cells (Yang et al., 2018). Besides EV-miRs, other groups have also shown HIV
proteins (McNamara et al., 2018),(Arakelyan et al., 2017; Rahimian and He, 2016) could
be packaged into the exosomes and spread among cells, contributing to the pathogenic
effect. Those studies have indicated the EVs play an essential role in mediating the
neuropathology.
1.9 EVs for treating neuroinflammation

Owing to the tight BBB, a lot of drugs can not reach the brain. In the filed targeting
therapeutic drugs to the CNS is still a major challenge. Recently the EVs are showing
potential to be as promising vehicles for the drug delivery through the BBB according to
their bioavailability and innate biological nature(Gupta and Pulliam, 2014; Hu et al., 2016b;

13
Sil et al., 2019). The study done by Sun et al. has shown curcumin (an anti-inflammatory
nature compound) could be passively loaded within EVs that could increase the
bioavailability and stability of curcumin in vivo. Furthermore, EVs-curcumin showed
improved therapeutic efficacy that significantly improves survival in lipopolysaccharide
(LPS)-induced septicemia (Sun et al., 2010). Zhuang et al. have tried similar therapeutic
strategies, their study has shown that intranasal administration of curcumin-loaded EVs
could alleviate LPS-induced neuroinflammation in the mice brain (Zhuang et al., 2011).
siRNAs as the therapeutic reagents also can be loaded into the EVs to achieve the effect
of antiinflammation in the CNS. The group of Lydia Alvarez-Erviti et al. firstly development
a method to deliver siRNA via EV selectively into the CNS. The engineered dendritic cells
are made to express an exosomal membrane protein Lamp2b fused to the neuron-specific
RVG peptide3 that achieve targeting selectively in the CNS. Further, they used this
engineered exosome to carrier siRNA-BACE1 and successfully knocked down mRNA
(60%) and protein (62%) of BACE1 in the WT type mice (Alvarez-Erviti et al., 2011).
Besides exosome to be used as the delivery device of medicine, there is a growing number
of studies that demonstrated stem cell-derived EVs were showing the effect on antiinflammation. For example, Zhang et al., 2015 and Zhang et al. 2016 have shown that
human mesenchymal stem cells (MSCs)-derived EVs can suppress astroglial activation
that achieves to reduce the neuroinflammation in the TBI rat model significantly (Zhang et
al., 2015b; Zhang et al., 2017b). However, the cellular and molecular mechanisms are still
unclear. Several studies provide some ideas that MSCs-derived exosomes can inhibit proinflammatory effect through suppression of Toll-like receptor signaling (Phinney et al.,
2015) and inhibit hypoxic inflammation via suppression of STAT3 phosphorylation that
regulates pro-proliferative pathways (Lee et al., 2012). The EV cargoes such as miRs play
an essential role in regulating the phenotype and the cellular processes of the recipient
cell. Emerging shreds of evidence have demonstrated that EV-miRs involve in anti-
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inflammation. For example, Zhou Y et al. have shown Endothelial Progenitor Cells (EPC)derived exosomes are beneficial in sepsis via regulating endothelial cell function. They
found EPC-miR126-3p and -5p could respectively target vascular cell adhesion molecule
1 (VCAM1) and high mobility group box 1(HMGB1), that to achieve the effect of
suppressing endothelial activation and inflammation (Zhou et al., 2018a).
2. REGULATION OF MORPHINE INDUCED NEUROINFLAMMATION
2.1 Overview

A substantial proportion of AIDS cases are contributed by drug abusers in the
United States as well as all over the world (2017a; 2017b). The 30% of US injecting drug
users are reported HIV positive, and injection drug use is commonly contributing to
explosive growth in new HIV infections in many parts of the world (UNAIDS, 2006), such
as parts of Asia and Eastern Europe. Morphine and heroin, opiates, are drugs of choice
in a large number of injecting drug users. A strong connection has been found between
opiate usage and HIV-1 neuropathogenesis, and opiate use has been showed to correlate
with increased severity of CNS disease through a few potential mechanisms (Bell et al.,
2006; Gurwell et al., 2001; Hu et al., 2005; Royal et al., 2003). Morphine as an opioid
analgesic that is extensively used in the setting of the clinic (FDA, 2016). Because of
multiple factors (morphine dosage, premorbid susceptibility, multidrug usage, nutritional
status) are beyond control in clinical settings. Thus studies on the interplay between HIV
pathogenesis and opiate abuse in humans considered being a challenge. The elegant
nonhuman primate (NHP) models have been developed to circumvent the challenge and
overcome the limitation that was used in HIV/AIDS research to unravel the complexities
of the human condition (Burdo et al., 2010; Clements et al., 2011; Williams and Burdo,
2009). We were using one such well-established NHP model to demonstrate that
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morphine could exacerbate both the peripheral and the CNS virus load, which, in turn,
leading to an acceleration of SIV-neuropathogenesis(Bokhari et al., 2011). Therefore, the
next logical step is of paramount importance to understand the mechanism(s) by which
HIV/HIV proteins and opiates in mediating disease progression and pathogenesis. These
studies will provide information that could be the basis for future therapeutic modalities
development.
Both clinical & animal studies indicate that opioid-induced neuroinflammation plays
an essential role in the progressive degeneration of brain tissue in morphine use disorders
(Ghavimi et al., 2015; Jokinen et al., 2018; Mansouri et al., 2018; Pan et al., 2016; Sil et
al., 2018; Tian et al., 2015b; Watkins et al., 2009). Neuroinflammation, an inflammatory
response within nervous tissue, is triggered by a variety of endogenous and exogenous
sources, such as invading pathogens, toxic molecules, and neuronal injury (Chen et al.,
2018). It is characterized by the activation of glial cells (Guo et al., 2015; Guo et al., 2016;
Hu et al., 2017; Jha et al., 2012; Periyasamy et al., 2018), the release of inflammatory
molecules (Liao et al., 2016), the disruption of BBB (Bowman et al., 2018), and the influx
of peripheral immune cells into the brain (Niu et al., 2019). The next, we will discuss how
morphine regulates neuroinflammation.
2.2 Morphine-mediated dysregulation of microglia

Glial cells, particularly microglia, play essential roles in brain homeostasis and
functionality (Yin et al., 2017). Microglia are known as a critical player in the removal of
dead, dying, infected, or microbes that are essential for brain homeostasis. The “find me-”
and “eat-me” signals were well studied to demonstrate how apoptotic cells (majorly are
neurons) send the message to attract the glial cells, which, in turn, results in the
engulfment and clearance of apoptotic cells tissue homeostasis (Segawa and Nagata,
2015; Zagorska et al., 2014). However, in the CNS, the phagocytosis-impaired microglia
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loss ability to clear toxic pathogens and cellular debris, which, in turn, leads to toxic
neuroinflammation that contributes to the pathogenesis of various neurodegenerative
disorders (Amor et al., 2010; Glass et al., 2010). The elegant studies were done by
Ninković et al. (Ninkovic and Roy, 2012) they demonstrated exposure of morphine resulted
in impairment of bacterial phagocytosis by macrophages. The further mechanism study
showed this effect was opioid receptors-dependent induced inhibition of actin
polymerization and pathogen internalization. Intriguingly, Jung-Hee Ryu et al. (Ryu et al.,
2018) did another study; they found morphine could reduce LPS-mediated microglial
phagocytosis via opioid receptor-dependent P38 MAPK inhibition. According to these
findings,

thus

suggested

that

the

morphine-mediated

suppression

of

macrophage/microglial phagocytosis and pathogen clearance, which, in turn, lead to
worsened pathogenesis of the disease. The following thesis project is undertaken to
understand how EV-mediated astrocyte-microglial crosstalk results in impairment of
microglial phagocytosis in the context of morphine exposure.
Continual microglial activation contributes to chronic neuroinflammation that
underlies various neurodegenerative diseases (Sochocka et al., 2017). A large number
of studies demonstrated morphine could induce microglial activation. For example, Liang
Y et al. have shown that exposure of microglia to morphine could trigger TLR4
internalization that results in the increased synthesis of IL-1β while stimulating the release
of IL-1β through the P2X4R-dependent signaling pathway (Liang et al., 2016). Besides
morphine mediates TLR4 internalization, there are several groups demonstrated
morphine could bind to myeloid differentiation factor-2 (MD-2) of the innate immune
receptor TLR4 supported by in silico model, in vivo and biophysical assays, which, in turn,
leads to activation of the TLR4 signaling that results in a pro-inflammatory response in
glial cells (Eidson and Murphy, 2013; Shah et al., 2016; Wang et al., 2012). Instead of
those mechanisms by which morphine directly induce microglial activation, there are few
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study focus on how cellular crosstalk contribute to microglial activation; the following thesis
project is undertaken to understand how EV-mediated astrocyte-microglial crosstalk
resulted in microglial activation in the context of morphine exposure (Figure 1).
2.3 Morphine-mediated the disruption of BBB and influx of monocyte.

The breach of BBB with an increased influx monocyte is a well-accepted hallmark
feature for the development of neuroinflammation (Bethel-Brown et al., 2012; Floris et al.,
2004; Smith et al., 2018). A subset of circulating white blood cells, monocytes can migrate
across the BBB under pathological conditions and the infiltration of monocytes is
implicated in the progression of many CNS neurodegenerative diseases, such as
Parkinson’s disease(Wijeyekoon et al., 2018), Alzheimer’s disease(Theriault et al., 2015),
multiple sclerosis(Filion et al., 2003), and HAND(Burdo et al., 2013; Napuri et al., 2013;
Veenstra et al., 2017; Yadav et al., 2016; Yao et al., 2010). Intriguingly, morphine has not
only been found to enhance HIV-1 infectivity of monocyte-derived dendritic cells and
macrophages (Reynolds et al., 2012) but also been shown to facilitate infiltration of
monocyte across the BBB into CNS, leading, in turn, to enhanced HIV disease progression
and increased neuropathology (Bokhari et al., 2011; Dutta and Roy, 2015). The
mechanisms by which morphine elicits these responses, however, remain poorly
understood.
There are several papers demonstrated that exposure brain vascular endothelial
cells to morphine could induce an increased release of proinflammatory mediators as well
as a breach of the endothelial barrier (Mahajan et al., 2008; Wang et al., 2012; Wen et al.,
2011). The focus of those studies is majorly on examining the role of brain vascular
endothelial cells in mediating neuroinflammation. However, there is one overlooked cell
type pericyte that is uniquely positioned within the brain microvascular and as an essential
player in the development and maintenance of the cerebrovascular unit (Sweeney et al.,
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2016). Pericytes are starting to be well-known functioning as integrators, coordinators,
and effectors of the BBB, which in turn regulates the permeability of the barrier, the
cerebral blood flow, and toxic product clearance(Niu et al., 2014). Recently studies provide
compelling evidence that pericyte loss results in increased extravasation of peripheral
immune cells as well as elevated levels of CSF sPDGFRβ, which has been implicated as
a biomarker of human cognitive dysfunction (Montagne et al., 2015; Nation et al., 2019).
EVs comprising of microvesicles, exosomes, & apoptotic bodies are thought to play
essential roles as cargo-carrying vesicles mediating communication among different cell
types and tissues (Lee et al., 2018), including the CNS(Hu et al., 2016b). EVs are a crucial
player in cell-to-cell communication by transporting their cargo comprising of proteins,
lipids, and RNAs to remote cells through receptor-ligand interactions. In keeping with the
increasing interest in molecular mechanisms controlling neuroinflammation, an emerging
aspect of gene regulation has gained attention with the discovery of mammalian miRs.
MiRs are small and evolutionarily conserved noncoding RNAs that are derived from much
larger primary transcripts. The dysregulation of miRs has been associated with viralinduced neuroinflammation and neurodegenerative processes (Mishra et al., 2012).
Newer targets and functions of miRs are continually being explored and discovered. The
overarching goal of our aim is to examine yet another undefined role of morphinemediated upregulation and release of extracellular miRs in regulating pericyte function(s)
that implicate the neuroinflammation (Figure 1).
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Figure 1 Schematic of morphine-mediated neuroinflammation involves ADEVs.
Neuroinflammation induced by morphine involves novel mechanism (s) that 1)
Morphine induces upregulation and release of AU, GU-riched miRs in ADEVs that can be
taken up by microglial cells and reach endosomal TLR7, which, leading, in turn, to
upregulation of lincRNA-Cox2 expression via activating TLR7/NFκB pathway, ultimately
resulting in impaired microglial phagocytosis; 2) Morphine induces the expression of miR138 in morphine-stimulated ADEVs, which can be taken up by microglial cells. Mor-ADEV
containing miR138, lead, in turn, activates the TLR7-NF-kB axis and induces the
expression and release of IL6 / TNFα, finally causes microglial activation; 3) exposure of
morphine induces the expression and release of miR-23a in the ADEVs, which, upon
uptake by pericytes, downregulating of PTEN that results in induction of pericyte migration
thus lead to influx of monocyte.
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3. MATERIALS AND METHODS
3.1 Reagents

Morphine was purchased from R&D Systems (Minneapolis, MN, USA). Chemical
inhibitors, including the opioid receptor antagonist naltrexone, endosomal TLR inhibitor
Chloroquine, IKK-2 inhibitor SC514, mimic and inhibitor of hsa-miR-23a-3p were
purchased from Sigma-Aldrich (St. Louis, MO, USA). The hnRNP A2/B1 siRNA (h):sc43841 were purchased from Santa Cruz. DOTAP Liposomal Transfection Reagent was
also purchased from Sigma-Aldrich. The mouse IL-6 / TNFα DuoSet kits were obtained
from R&D Systems (Minneapolis, MN, USA). Exo-FectTM Exosome Transfection Kit was
purchased from SBI System Bioscience (Palo Alto, Canada). Cell Tracker Green CMFDA
and Red CMTPX were purchased from Invitrogen.

3.2 Animals

C57BL/6N WT mice (male, 6–8 weeks) were purchased from Charles River
Laboratories, Inc. (Wilmington, MA). We purchased Tlr7−/− mice from Jackson
Laboratories (Bar Harbor, ME, USA) and bred in the UNMC animal facility. Pregnant WT
mice were purchased from Charles River Laboratories. Mice with neural/glial antigen-2
expression (NG2 DsRed) provided red fluorescent-labeled pericytes for detecting in vivo.
DesRed-NG2 mice were purchased from Jackson Labs (Bar Harbor, ME) from stock
Tg(Cspg4-DsRed.T1)1Akik/J. As described from the provided company: NG2DsRedBAC
transgenic mice express DsRed.T1 (a red fluorescent protein variant) under the control of
the mouse NG2 (Cspg4) promoter/enhancer. All the animals were housed under
conditions of constant temperature and humidity on a 12 hrs light, 12 hrs dark cycle, with
lights on at 07:00. All animal procedures were performed following the protocols approved
by the Institutional Animal Care and Use Committee at the UNMC.
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3.3 Intranasal delivery of EVs in mice

C57BL/6N mice (male) were anesthetized and placed in a supine position in an
anesthesia chamber, followed by intranasal administration of EVs (20 µg/100 µL) in saline
as drops with a small pipette.
3.4 Cell cultures

A172 (American Type Culture Collection (ATCC), no. CRL-1620), the human
astrocytic cell line was cultured as described previously (Bethel-Brown et al., 2012) and
maintained in 10% heat-inactivated fetal bovine serum (FBS) DMEM with high glucose,
penicillin (100 U/mL), streptomycin (100 µg/mL) and 2 mM glutamine. In this study, A172
cells were used younger than 30 passages. We got human primary astrocytes (HA) from
ScienCell Research Laboratories (Carlsbad, CA, USA), and the HA cells were cultured in
astrocyte medium (ScienCell). For our study, we used the HA cells within 10 passages.
Mouse primary astrocytes were isolated from whole brains of post-natal (1- to 3day-old) C57BL/6N mice described as previously (Liao et al., 2016; Yao et al., 2014a) and
were positive for astrocyte marker GFAP. Cells were plated on poly-D-lysine pre-coated
cell culture flasks and were maintained in DMEM (100 U/mL penicillin,100 µg/mL
streptomycin and 10% FBS).
Microglial cell line BV-2 was generously provided by Dr. Sanjay Maggirwar
(University of Rochester Medical Center, Rochester, NY, USA). We maintained the BV2
cells in DMEM supplemented with 10% FBS, 100 µg/mL streptomycin and 100 U/mL
penicillin. In this study, we used BV-2 cells within passage 20.
Mouse primary microglial cells were isolated from 1- to 3-day-old C57BL/6N or
TLR7 KO newborn pups as described previously (Liao et al., 2016; Yao et al., 2014a).
After digestion, the dissected brain cortices were dissociated in Hank’s buffered salt
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solution supplemented with 0,25% trypsin. The cell suspension of mixed glial cells was
resuspended in DMEM supplemented with OPI supplement, 10% heat-inactivated FBS,
100 U/mL penicillin, and 100 µg/mL streptomycin. We plated the glial cells at the density
of 5 X 106 cells/flask onto 75-cm2 cell culture flasks. We changed cell culture medium every
5 days, and after the first medium change, to promote microglial proliferation, we added
macrophage colony-stimulating factor (M-CSF; 0.25 ng/mL; PeproTech, Rocky Hill, NJ,
USA) into the culture flasks. The microglia cells will be floating in the cell medium, and be
collected from each flask, followed by the collection of microglial cells using centrifugation
at 800 g for 5 min and then we plated the isolated microglia onto the cell culture plates.
HEK-Blue TLR7 and HEK-Blue Null cells were obtained from InvivoGen. We
cultured the cells in DMEM supplemented with 10% heat-inactivated FBS, 0.2% sodium
bicarbonate, 100 IU/mL penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine, 30 μg/mL
blasticidin, 100 μg/mL zeocin, and 100 μg/mL normoxia at 37 °C in humidified air
containing 5% CO2 as per the manufacturer’s instructions.
We purchased primary human brain vascular pericytes (HBVPs) from ScienCell
and cultured the cells in the pericyte medium (ScienCell). HBVPs were isolated from the
human fetal brain. And the purity of pericyte was validated (>98% purification) by our
previous study (Niu et al., 2019), demonstrating these pericyte cells were positive for
PDGFR-β, NG2, Desmin, and TBX18 of the pericyte markers. Additional, pericytes also
showed negligible staining for αSMcas well as the endothelial cell marker CD31. Cells
were cultured in dishes coated with poly-l-lysine (2µg/cm2; ScienCell), and cells were used
within passages 2–5.
3.5 EV isolation

We isolated EVs from the culture media of primary astrocytes and A172 cells using
differential centrifugations as previously described (Ye et al., 2018). In brief, culture media
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were collected, centrifuged at 1,000 X g for 15 min to get rid of live cells, and again spun
at 10,000 X g for 30 min, followed by filtration the supernatant through a 0.22-µm filter to
get rid of cell debris. EVs were pelleted by ultracentrifugation (Beckman 32Ti rotor;
Beckman Coulter, Brea, CA, USA) at 100,000 X g for 70 min. We characterized the EVs
using a BCA Protein Assay Kit (Pierce, Rockford, IL, USA) to check protein content, WB
to check exosome markers such as Alix, TSG101, and CD63. EVs were further quantified
by Nanoparticle Tracking Analysis (NTA) using ZetaView Particle Metrix, as previously
reported.
3.6 Electron microscopy

We prepared EV pellets for negative staining following a slightly modified procedure.
We used wide-bore tips to take 3 mL of EV pellet and gently placed EVs on 200-mesh
Formvar-coated copper grids, after 4–5 min adsorption, and we processed the EV
samples for standard uranyl acetate staining. In the end, We gave the grid three times
washing with PBS, followed by a semi-dry of the grid at room temperature and observation
of EVs using TEM (Hitachi H7500 TEM; Hitachi, Tokyo, Japan).
3.7 Atomic force microscopy

The 1-(3-aminopropyl) silatrane (APS) mica functionalization procedure was used,
in which freshly cleaved mica is treated with APS, as previously described (Banerjee et
al., 2017; Lyubchenko et al., 2011) Twenty microliters (8.3 ×10^9 EVs/mL) of EV sample
was deposited on APS mica for 20 min at room temperature. Then we added 200 ml of
the PBS buffer to the sample, followed by an assessment of the EV samples using AFM
imaging. We used the Asylum Research MFP3D (Santa Barbara, CA, USA) instrument
for the AFM imaging of EVs. The analysis of AFM imaging was assessed in tapping mode
at room temperature. An MSNL probe with cantilever “E” (Bruker Corporation) was
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employed for imaging. The nominal spring constant of the MSNL “E” cantilevers was ~0.1
N/m.
3.8 RNA isolation and sequencing

RNA was extracted from EVs, which were isolated from conditioned media of
human primary astrocytes of three donors. RNA samples were then shipped on dry ice to
LC Sciences (Houston, TX, USA) for miRNA sequencing.
3.9 Oligos and plasmid transfection

Under

The

RNA

AGCUGGUGUUGUGAAUCAGGCCG),

oligos
miR-138

(miR-138

sequence:

(mutant-miR-138

sequence:

AGCUGGUGAATUGAAUCAGGCCG) and cy5 labelled oligoes were purchased from
Integrated Technologies (Coralville, Iowa). The custom-designed miR-23a-PTEN-Target
Protector

negative

control

(miR-23a-TP-ctrl:

scramble

sequence:

5’

GCCATCAAACTCTATAAATGCTGCTCT 3’) and miR-23a-PTEN-Target Protector (miR23a-PTEN-TP: 5’ CTTCACATTAGCTTTACAATAGTAGTT 3’) were purchased from
Integrated DNA Technologies. EVs were loaded with oligos using Exo-Fect Exosome
Transfection Reagent according to the manufacturer’s instructions. Anti-miR138 were
obtained from Integrated Technologies. pEF6. mCherry-TSG101 was a gift from Quan Lu
(Addgene plasmid 38318). Sequences of mouse Dicer1 siRNA oligonucleotides used in
this

study

were:

mouse

GrUrGrUrCrArUrCrUrUrGrCrGrArUrUrCrUrArUrUr-3’;
UrArGrArArUrCrGrCrArArGrArUrGrArCrArCrUrUr-3’;
CrCrArArCrUrArCrCrUrCrArUrArUrCrCrCrArUrUr-3’;
UrGrGrGrArUrArUrGrArGrGrUrArGrUrUrGrGrUrUr-3’.

5’-

Dicer1-siS1,
mouse
mouse
mouse

Dicer1-si

AS1,

Dicer1-siS1,
Dicer1-si

AS2,

5’5’5’-
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3.10

Luciferase activity assays

As described in our previous study (Yang et al., 2018), we did the modification.
Briefly,

a

38

bp

PTEN

3’UTR

segment

tcgaggcggccgcCTACTATTGTAAAGCTAATGTGAAT-3’

(sense

and

5’

antisense

5’-

CTAGATTCACATTAGCTTTACAATAGTAGGCGGCCGCC-3’) containing the putative
miR-23a target site was cloned into the XhoI and XbaI sites of the pmirGLO vector. For
3′UTR-miR-23a-target-mutant

pmirGLO-PTEN

tcgaggcggccgcCTACTATTGTAAAGCTTTACACTAT-3’

segment
and

(sense

5’-

antisense

5’-

CTAGATTCACATTAGCTTTACAATAGTAGGCGGCCGCC-3’), the miR-23a target site
(AATGTGA) within the PTEN 3′UTR was changed to (TTACACT). Followed the
manufacturer’s protocol (Promega), seeding the HEK293 cells into 24-well plates. Cotransfect either miR-23a mimic or scramble miRNA-control with either pmirGLO-PTEN3′UTR-miR-23a-target

or

pmirGLO-PTEN-3′UTR-miR-23a-target-mutant

luciferase

reporter vector using lipofectamine 3000 (Invitrogen) for two days, followed by an
assessment of the luciferase activity using the Dual-Luciferase Reporter Assay (Promega).
Firefly luciferase activity was normalized by renilla luciferase activity and expressed as a
percentage of the control (Triplicated independent experiment, performed in 3 wells each
time).
3.11

Western blotting

Brain tissues, treated cells, or EVs were lysed using the Mammalian Cell Lysis kit
(Sigma-Aldrich),

as

described

previously.

Proteins

in

equal

amounts

were

electrophoresed in an SDS-polyacrylamide gel under reducing conditions followed by
transfer to PVDF membranes. Blots were blocked with 5% BSA in TBS-Tween for 30 min,
followed by an incubation of antibodies specific for Iba-1 (1:1000; 019-19741; Wako),

27
Tsg101 (1:1,000; ab125011; Abcam, Cambridge, MA, USA), Alix (1:1,000, ab117600;
Abcam), CD63 (1:1,000; ab216130; Abcam), Flotillin (1:200, Cell Signalling Technology),
Calnexin (1:1500; C7617; Sigma-Aldrich), NF-κB p65 (1:2,000; ab16502; Abcam), Histone
H3 (1:1,000; 9715S; Cell Signaling Technology), hnRNP A2/B1 (1:1000; sc-53531; Santa
Cruz), PTEN (1:1000; ab32199; Abcam), p-Akt (1:1000; 9271S ; Cell Signaling), Akt
(1:1000; 9272S; Cell Signaling) and β-actin (1:5,000; A5316; Sigma-Aldrich). Secondary
antibodies were alkaline phosphatase-conjugated to goat anti-mouse/rabbit IgG (1:10,000;
Jackson ImmunoResearch Labs). Signals were detected by SuperSignal West Dura
Extended Duration or Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific).
All experiments had at least four biological replicates, and representative blots are
presented in the figures.
3.12

Real-time PCR

Comparative real-time PCR was performed with the use of Taqman Universal PCR
Master Mix (Applied Biosystems) for quantitative analysis of mRNA expression. Specific
primers and probes for IL-6, TNFα, GAPDH, mature miR-138, mature miR-23a, and primiR23a and snRNA RNU6B (U6) were obtained from Applied Biosystems. All reactions
were run in triplicate. The amount of miRNA was obtained by normalizing to snRNA
RNU6B and relative to control as previously reported (Hu et al., 2017).
3.13

In situ hybridization and immunostaining

Human primary astrocytes were fixed and prehybridized in hybridization buffer (50%
formamide, 200 μg ml−1 yeast tRNA, 10 mM Tris-HCl, pH 8.0, 1 × Denhardt’s solution,
600 mM NaCl,1 mM EDTA, 0.25% SDS, 10% Dextran sulfate) at a concentration of 9 pM
for the commercially available digoxigenin-labeled miR-138 probe or miR-23a probe
(Exiqon). LNA-modified miR-138, labeled at both the 5′ and 3′ ends with digoxigenin
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(Exiqon), followed dilution to the final concentration at 2 pM in hybridization buffer.
Subsequently, the probes in hybridization buffer were added and incubated in a humid
chamber overnight at 37 °C. Then, we washed the slides three times in 2× SSC for 2 min
each at 42°C and in 0.2× SSC for 2 min each at 42°C. The slides were then blocked with
blocking buffer (3% normal goat serum and 1% bovine serum albumin in 1 × PBS) for 1 hr
at room temperature, followed by an incubation with anti-digoxigenin conjugated with
horseradish peroxidase (1:100, Roche Diagnostics, Mannheim, Germany) and anti-GFAP
(1:200, G3893, Sigma-Aldrich) antibodies overnight at 4 °C. The slides were washed twice
with PBS, followed by incubation with Alexa Fluor 488 goat anti-rabbit IgG (1:200,
Invitrogen, Carlsbad, CA) antibody for 1 hr at room temperature. Then washed twice in
PBS and the signal amplification using TSA Cy5 kit (PerkinElmer, Waltham, MA). Then,
we mounted the slides using Prolong gold anti-fade reagent with DAPI (Invitrogen). The
specificity of the miR-138 signal in FISH experiments was confirmed when compared with
scrambled control. Unlike the miR-138, the scramble probe showed no signal in astrocytes.
3.14

Phagocytosis Assay

We examined the phagocytic activity of adult microglia of live brain slices followed
the method as described previously (Krabbe et al., 2013; Minami et al., 2014). We took
out the brains from 8-week-old mice, then the brains were rinsed in carbogen-saturated
(5% CO2 and 95% O2) artificial cerebrospinal fluid (ACSF) containing (in mM): KCl 2.5;
NaCl 126; CaCl2 2.5; MgSO4 1.3; NaHCO3 26; NaH2PO4 1.25; and D-glucose 10 (pH
7.4; all from Sigma). Next, we prepared coronal slices (130 mm) using a Vibratome
(Microm, Walldorf, Germany) at 4℃ and allowed the slices to rest in ACSF buffer at room
temperature for 1 hr, followed by an incubation with fluorescein isothiocyanate (FITC)labeled rabbit IgG-coated latex beads in size about 0.1 mm (mean particle size) (1:100;
Cayman Chemical) for 60 min at 37℃. Then, we gave the slices three times wash and
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those slides were fixed with 4% paraformaldehyde.
Next, to visualize microglia ex vivo, the slices were permeabilized (0.25% Triton
X-100, 1% BSA, and 10% goat serum in PBS), followed by incubation with anti-Iba1 (1:750;
Wako) for overnight at 4 ℃, goat anti-rabbit Alexa 488 (1:250; Invitrogen) for 1 hr at room
temperature. And the last, we mounted the slices using Prolong gold anti-fade reagent
with DAPI (Invitrogen). The observation of fluorescent images was acquired at room
temperature using a Zeiss Observer Z1 microscope (Carl Zeiss, Germany), followed by
the analysis of images using AxioVs 40 4.8.0.0 software (Carl Zeiss MicroImaging).
To examine the ability of microglia to phagocytose particles, we seeded microglial
cells (2 × 10^5 cells/mL) onto a 24-well plate and let the cells adhere overnight, followed
by incubation of cells with FITC-labeled rabbit IgG-coated latex beads as described above,
three times washed, and finally visualized at 20 magnification with a microscope.
3.15 RNA immunoprecipitation

BV-2 cells were treated with the indicated miRNAs using Dotap and incubated at
37℃ for 20 min. Cells were then extensively washed with 1.5 ml of ice-cold PBS, collected,
and lysis performed through a 5 min incubation with 150 μl of Polysome lysis buffer on ice.
Lysates were finally frozen in dry ice for 1 h, and then harvested at 14,000 g for 15 min.
100 μl of each lysate was added to 50 μl of A/G protein (Santa Cruz), which was previously
preincubated with 25 μl of NT2 buffer 5% BSA for 1h and then with 100 μl of anti-TLR7
antibody in rotation at 4 ℃ overnight. Lysates were further incubated with beads
(extensively washed with NT2 buffer, according to the manufacturer’s protocol) (Mylteni)
in a final volume of 850 μl of NT2 buffer supplemented with 1 μl of 1M DTT and 34 μl of
0.5M EDTA. Immunoprecipitation was performed for 5h at 4℃ in rotation. Beads were
washed 4x with NT2 buffer and was incubated with 100 μl of NT2 buffer and Proteinase K
(Qiagen) at 55 ℃ for 30 min, then RNA was extracted with Trizol and processed for real-
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time analysis.
3.16 Biotinylated miRNA pull-down
BV-2 cells were transfected with 5’-biotinylated mature miR-138 and mut-miR-138
(20 µM final concentration) by Lipofectamine RNAiMax for 24 hr. For a 10 cm dish, 50 µL
of pre-washed and blocked streptavidin agarose beads (Thermo Scientific) were
incubated with the cell lysates at room temperature for 2 hr, according to the
manufacturer’s instructions. Beads were washed three times and followed by adding 50
µL 2X loading buffer. The samples were heated for 5 min at 95 ℃ and proceed to Western
blotting to detect TLR7 using the anti-TLR7 antibody.
3.17 Quanti-Blue® SEAP reporter assay

BV-2 HEK-Blue-Null1-v and HEK-Blue mTLR7 cells (1 × 104) were plated in 96well plates and grown to 70 % confluence. Cells were then stimulated with Dotap-miR138,
Dotap-mut-miR138, EV-miR138, EV-mut-miR138 for 16 h. CL294, TLR7 agonist were
also given to cells as a positive control. Aliquots of the culture medium (20 μl) were
removed and added to new 96-well plates containing 180 μl of pre-warmed Quanti-Blue™,
a SEAP colorimetric detection medium, as per manufacturer’s instructions. The color was
allowed to develop for 1 h, and absorbance was read at 650 nm in a Bio-Tek ® microplate
reader (Burlington, VT).
3.18 Immunostaining and image analysis

Formalin-fixed, paraffin-embedded (FFPE) blocks were sectioned at 4µm and
stained with antibody specific for Iba1 (1:250; Wako) overnight at 4℃. The next day,
sections were washed with PBS for three times, followed by incubation with biotinylated
goat anti-rabbit immunoglobulin G (1:200) in immunoblotting buffer at RT for 1 h, and
sequentially the slides were incubated with an avidin-biotin-peroxidase kit for 1 h. The last,
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horseradish peroxidase reaction product was visualized with an enhanced DAB
peroxidase substrate kit, followed an assessment by the Ventana iScan HT slide scanner
(Roche, Basel, Switzerland) at 40X magnification. The morphology of microglia in various
regions including cortex, hippocampus, thalamus, the striatum was quantified by Image J
followed by the method described previously (Fernandez-Arjona et al., 2017; Young and
Morrison, 2018)
Mouse primary microglia or BV2 cells were cultured on coverslips, followed by
fixation with 4% formaldehyde for 20 min at room temperature. We gave the slides or
coverslips three times wash with PBS, followed by permeabilization with 0.3% Triton X100 for 30 min, rewashing three times, and blocked in 10% goat serum in PBS for 2 hr at
RT. The following antibodies were used for immunostaining: Iba1 (1:250; Wako), NG2
(1;1000; ab5320; Abcam ), PDGFR-β (1:1000; ab32570; Abcam), CD31 (1:1000;
ab24590; Abcam), EEA1 (1:100; #3288; Cell signaling ), NF-κB (1:100; ab16502; Abcam),
TLR7 (1:100; ab45371; Abcam). The slides or coverslips were washed three times with
PBS, followed by incubation with Alexa Fluor 488–conjugated anti-rabbit or anti-mouse
(Invitrogen) for 1 hr at RT. After a final washing with PBS three times, the slides or
coverslips were mounted using Prolong Gold Antifade Reagent (Invitrogen). Fluorescent
images were taken at RT on a Zeiss Observer, under the condition of a Z1 inverted
microscope with a 40×/1.3 or 63×/1.4 oil-immersion objective. The images were analyzed
with ImageJ software.
3.19 Adult microglia isolation

From whole-brain homogenates, we isolated microglia using a method of percoll
gradient centrifugation according to the previous reports (Guo et al., 2016; Yao et al.,
2014b) with slight modifications. Briefly, we homogenized the brains in PBS (pH 7.4) by
passing through a 70-μm nylon cell strainer for 23 times, followed by centrifugation of
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resulting homogenates at 600 g for 6 min. Resuspension of cell pellets in 70% isotonic
Percoll (GE-healthcare, Uppsala, Sweden) at room temperature, followed by creating a
discontinuous Percoll density gradient layers at the concentration of 70, 50, 35, and 0%
isotonic Percoll. Sequentially, the gradient was went through centrifugation at 2,000 g for
20 min, followed by a collection of microglia from the interphase between the 70 and 50%
Percoll layers. Then, cells were washed three times and resuspended in sterile PBS,
followed by sorting out of CD11b+/CD45low population (microglia) using flow cytometry.
3.20 Brain microvessels isolation

Mouse and macaque brain microvessels were isolated following a differential
centrifugation protocol as described previously (Niu et al., 2015). Briefly, the brains were
removed and immediately immersed in ice-cold isolation buffer A (4.7 mM KCl, 103 mM
NaCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, and 15 mM HEPES, pH 7.4),
followed by the removal of the cerebellum, olfactory bulb, and meninges. Subsequently,
the brains were homogenized in 2.5 ml of isolation buffer B (10 mM glucose, 25 mM
NaHCO3, 1 mM Na pyruvate, and 10 g/L Dextran, pH 7.4) containing protease inhibitors.
The homogenates were added to Dextran (6 ml; 26%) and centrifugated for 20 min at
5800 × g. Pellets were resuspended in isolation buffer B, followed by filtration through a
70-μm mesh filter. Isolated brain microvessels were then harvested from the filtered
homogenates by centrifugation. Some pure brain microvessels were used for immunostaining by spreading on glass slides and prepared for PECAM1/CD31, and PDGFR-β
detection.
3.21 Wound-healing assay.

According to the instructions of the manufacturer as well as our previous study (Niu
et al., 2014), briefly, 600 μl cell suspension of HBVP with concentration 4 × 10^5 cells/ml
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was plated to 24-well plate to form the monolayer within the wound field. Exposure of the
cells to control-ADEVs or morphine-ADEVs for 16 h and monitored for migration after
stopping the reaction by staining buffer. Then we have subsequently taken images using
the Olympus DP71 microscope. We got the statistical data on the percentage of migrated
cells using Image J.
3.22 Bone marrow-derived monocyte (BMM) isolation

According to our previous study (Niu et al., 2019), we used C57BL/6N mice
(Jackson Laboratory), 6–8 wk of age, as BMM donors. Briefly, first removed the femur,
followed by dissociating bone marrow cells into single-cell suspensions. Sequentially, the
single-cell suspensions of bone marrow cells were cultured for 5 d supplemented with
1,000 U/ml of macrophage colony-stimulating factor.
3.23 Trans-well migration assay
The migration of pericyte in vitro was determined using Falcon® Permeable
Support for 24-well Plate with 8.0 µm. Briefly, resuspension of pericyte in culture media
with 2% FBS at the concentration of 5×10^4/ml, followed by seeding 200 µl of cell
suspension into the upper compartment of inserts and exposed to either CTL-ADEVs or
morphine-ADEVs, 500µl of pericyte culture media added to the lower chamber. The cells
and transwell were incubated for 24 hrs at 37°𝐶. Sequentially, the insert with the cells were
stained with Cell Stain and the cells remaining in the pside of ithe nsert were removed,
followed by an assessment of pericyte migration using either images analysis or
measuring the extracted stain from migrated cells using a Synergy Mx fluorescence plate
reader (BioTek Instruments, Winooski, VT).
3.24 Endothelial cell-pericyte 3D co-culture model
Thaw BD Matrigel matrix (BDbioscience cat No. 354234 overnight on the ice at
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4°𝐶. Keep the Matrigel™ solution in an ice bath and remove 80μl using a cold pipet tip.
Quickly and carefully, transfer the matrigel to a 96-well plate. Be sure to remove any air
bubbles before gel polymerizes and Incubate the 96-well plate at 37°𝐶 for 1 hour. Harvest
cells and prelabel cells with cell tracker (Pericyte labeled with Green CMFDA and
endothelial cells labeled with Red CMTPX). Then mix the pericyte and endothelial cells
together at the concentration of pericyte at 4×10^5 cells/ml and endothelial cells at 1.6 ×
10^6, followed by add 200ul cell suspension to each Matrigel™ coated well and incubate
16-18 hrs at 37°𝐶.
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CHAPTER III
ROLE OF ADEVS IN MORPHINEMEDIATED MICROGLIAL
PHAGOCYTOSIS ALTERATION:
IMPLICATION FOR
NEUROINFLAMMATION
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4.

Morphine-exposed ADEVs induce alteration of microglial phagocytosis in vitro

Astrocytes are the most abundant fraction of glial cell types in the CNS (Ransom,
2004) with homeostatic functions such as maintenance of water and ion balance, removal
of extracellular glutamate, and release of neurotrophic factors. Intriguingly, according to
work done by Judith M. Silverman et al. suggested the primary EV source is astrocyte in
the brain (Silverman et al., 2019). In addition, our previous study has demonstrated
astrocyte-derived EV-miR-29b mediates HIV Tat and morphine-induced neuronal injury
via suppression of the neuroprotective protein platelet-derived growth factor (PDGF)-B
expression in the neuron. We sought to check whether morphine-exposed ADVEs affect
microglial phagocytosis. Herein we first to isolate EVs from culture media of human
astrocyte A172 cell, mouse primary as well as human primary astrocyte using a differential
ultracentrifugation procedure (Figure 2A). Next, isolated EVs were characterized using
western blot to check exosome markers, using transmission electron microscopy (TEM)
and atomic force microscopy (AFM) to check morphology of EVs. As shown in Figure 2B,
immunoblotting of EV lysates revealed the presence of exosomal markers such as Alix,
CD63, and TSG101 rather than Calnexin (endoplasmic reticulum protein, non-exosomal
protein). Additionally, as shown in Figure. 2C and 2D, characterization of EVs using TEM
and AFM showed spherical-shaped EVs ranging in size from 40 to 100 nm in diameter.
Next, we sought to check the effect of morphine on the number and size distribution of
ADEVs using nanoparticle tracking analysis (NTA), which showed EVs with the expected
size (no difference between morphine-exposed astrocyte and control cells) and
significantly increased numbers of released ADEVs in the presence of morphine (10 μM,
24 hrs)(Figures 2E and 2F).
We next asked whether microglial cells take up ADEVs that result in alteration of
microglial phagocytosis. For this, mouse primary microglia were incubated with ADEVs
isolated from mouse primary astrocyte that transfected with a plasmid encoding TSG101
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(exosomal marker) fused with mCherry. As shown in Figure 3, after microglia incubation
with TSG101-mCherry-tagged ADEVs, we can detect a fine granular fluorescent signal
within the cytoplasm. It indicated that ADEVs could be taken up by the microglia.
Furthermore, mouse primary microglial cells were exposed to PKH26-labelled ADEVs
(isolated from Control or morphine-exposed mouse primary astrocytes) for 24 hr, following
to add fluorescent beads and incubate with the microglial cells for 2 hrs. As shown in
Figure 4, exposure of morphine-ADEVs (red) to microglia resulted in decreased
internalization of the beads (green) compared with microglia exposed with control-ADEVs,
suggesting morphine-ADEVs could induce impairment of microglial phagocytosis.
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Figure 2 Characterization of EVs isolated from astrocyte culture
(A) Schematic representation of the major steps involved in the EV isolation from
astrocyte culture. (B) Western blot characterization of astrocyte EVs. Protein isolated from
astrocyte EVs were separated on SDS-PAGE and electroblotted onto a nitrocellulose
membrane. Blots were probed with exosome marker antibody against TSG101, CD63,
and Alix. Calnexin was used as a control for cell debris contamination. (C) Representative
electron micrograph of EVs isolated from A172 cells. Scale bar, 200 nm. (D) AFM image
of EVs isolated from mouse primary astrocyte culture supernatants. (E) Size and particle
distribution plots of isolated EVs from cell culture by NanoSight Tracking Analysis (NTA).
The plot shows a peak size of around 80 nm for isolated EVs. (F) Number of EVs isolated
from control and morphine-exposed human primary astrocytes. All experiments were done
at least three independent times. Data are shown as mean ± SEM. *p < 0.05 versus control
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Figure 3 ADEVs are taken up by microglial cells.
Mouse primary microglial cells were incubated with ADEVs isolated from the
plasmid of TSG101-mCherry-transfected mouse primary astrocytes for 20 min.
Paraformaldehyde fixed microglia were permeabilized and stained for microglial marker
Iba1, followed by FITC-conjugated secondary antibody and visualized by fluorescence
microscopy. Scale bars, 10 μm.
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Figure 4 Morphine-ADEVs induces impairment of microglial phagocytosis.
Mouse primary microglial cells were exposed to PKH26 labeled ADEVs isolated
from control, or Morphine-exposed mouse primary astrocyte (24 hrs) and subsequently
incubated with fluorescent beads for 2 h. The cells were then fixed and stained with DAPI
and analyzed for phagocytosis using fluorescence microscopy. Scale bar=5 μm.
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5.

The mechanism by which morphine-ADEVs-mediated impaired phagocytic

activity of microglia involves lincRNA-Cox2.
Having determined that exposure of morphine-ADEVs to microglia was able to
induced impaired microglial phagocytic activity. Next, we sought to figure out what is the
mechanism underlying this finding. Long non-coding RNAs (lncRNAs), such as long
intergenic non-coding RNAs (lincRNAs), are greater than 200 nucleotides that involved in
many cellular processes. Additionally, Dysregulation of lncRNAs has been shown to
underline various neurodegenerative disorders, such as Alzheimer’s (Faghihi et al., 2008),
Huntington’s (Lin et al., 2014) and Parkinson’s (Zhang et al., 2017a) diseases. Previous
studies have demonstrated lincRNA-Cox2 controlled the inflammatory response in
phagocytic (microglia and macrophages) as well as epithelial cells (Carpenter et al., 2013;
Hu et al., 2016a; Tong et al., 2016; Xue et al., 2019). However, the role of lincRNA-Cox2
in microglial phagocytotic activity remains unknown. To examine whether MorphineADEVs-mediated inhibition of microglial phagocytosis involves lincRNA-Cox2. Firstly, we
designed two lincRNA-Cox2 siRNAs and checked their knockdown efficiency in siRNAtransfected BV-2 microglial cells using real-time PCR. As shown in Figure 5A, both selfdesigned lincRNA-Cox2 siRNAs worked successfully reduced the expression of lincRNACox2 in microglia.
Next, we performed a microarray analysis to profile and compare the gene
expression between control and lincRNA-Cox2 knockdown BV-2 microglia. Intriguingly,
we identified a total of 20 phagocytosis-related genes in our samples. And 15 out of those
20 genes are negatively regulated by lincRNA-COX2, indicating knocking down of lincRNA
COX2 could result in increased microglial phagocytosis (Figure 5B).
Furthermore, the microglial cells were transfected with siRNA-Control or siRNAlincRNA COX2 for 24 hrs, followed by exposure of control-ADEVs or morphine-ADEVs for
4h and subsequently assessed and validated the expression of Lrp, Pld2, and Syk using

42
RT-PCR. As demonstrated in Figure 5C, morphine-ADEVs exposure of microglia resulted
in the downregulated expression of Lrp1, Pld2 and Syk compared with the microglia
exposed to control-ADEVs. Additionally, knocking down of lincRNA-COX2 significantly
upregulated expression of Lrp1, Pld2 and Syk in microglia exposed to either control- or
morphine-ADEVs.
According to these findings, we hypothesized that morphine-ADEVs-mediated
inhibition of microglial phagocytosis might involve in lincRNA-COX2 via its negatively
regulating phagocytosis-related genes. Further to tested our hypothesis, microglial cells
were transfected with either control- or lincRNACox2-siRNA for 24hrs, followed by
exposure of either control-ADEVs or morphine-ADEVs for another 24 hrs. Sequentially,
the microglial cells were incubated with fluorescently labeled IgG-opsonized latex beads
for 2 hrs, followed by washing and fixing of the cells. Fixed cells were then stained with
DAPI and assessed microglial phagocytotic activity using fluorescence microscopy and a
fluorometric plate reader. As shown in Figures 5D and E, morphine-ADEVs exposed
microglial cells resulted in significantly decreased internalization (40% inhibition) of IgGopsonized latex beads compared with the microglia exposed to control-ADEVs.
Additionally, morphine-ADVEs failed to inhibit the internalization of fluorescent latex beads
in microglia with knockdown of lincRNA-Cox2 (Figure 5D & E). In addition, to further
confirm that lincRNA-Cox2 does involve in morphine-ADEVs-mediated impairment of
microglial phagocytosis. Mouse primary microglial cells were transfected with either
control- or lincRNA-Cox2 siRNAs for 24h. Then exposure of PKH26-labeled ADEVs
(control- or morphine-ADEVs) to those microglial cells for another 24h, followed by
incubating with fluorescent beads for 2 hr. Again, there was reduced internalization of the
beads (green) in morphine- ADEV (red)-exposed to microglia compared with cells
exposed to control-ADEVs (red). Meanwhile, knockdown of lincRNA-Cox2 in microglial
cells, however, morphine-ADEVs (red) failed to reduce internalization of beads (green)
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compared with cells transfected with control- siRNA and exposed to morphine-ADEVs
(red)(Figure 5F). These findings thus underpinned the roles of both morphine-ADEVs and
lincRNA-Cox2 in microglial phagocytosis.
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Figure 5 Knockdown of lincRNA-Cox2 restores EV-mediated impairment of microglial
phagocytosis in vitro.
(A) Real-time PCR for lincRNA-Cox2 in microglia transfected with lincRNA-Cox2
siRNA. (B) Heatmap of differentially expressed phagocytosis-associated genes in
lincRNACox2 knockdown BV-2 cells compared with control cells. (C) Mouse primary
microglial cells were transfected with lincRNA-Cox2 siRNA for 24 hr, followed by exposure
of cells to astrocyte EVs for 4 hr, and subsequently assessed for the expression of Lrp,
Pld2, and Syk by qPCR. (D, E) BV-2 cells were transfected with either siRNA-control or
silincRNA-Cox2. Second day cells were exposed to EVs isolated from morphine exposed
astrocytes for 24 h followed by exposure of cells to fluorescent beads for 2 h. (D) The cells
were then fixed and stained with DAPI, and analyzed for phagocytosis of the beads using
fluorescence microscopy. Scale bar=50 μm. (B) Phagocytosis was also measured using
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a fluorometric plate reader. (F) Mouse primary microglial cells were transfected with either
control- or lincRNA-Cox2 siRNA for 24 h followed by exposure to PKH26 labeled EVs
isolated from mouse primary astrocytes (24 h) and subsequently incubated with
fluorescent beads for 2 h. The cells were then fixed and stained with DAPI, and analyzed
for phagocytosis using fluorescence microscopy. Scale bar=5 μm.
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6. The mechanism by which morphine-ADEVs-mediated induction of lincRNACox2 in microglia involves activation of TLR7/NFkB pathway
Having determined that lincRNA-COX2 plays a role in morphine-ADEVs-mediated
impaired microglial phagocytic activity. Next, we sought to explore how morphine-ADEVs
regulate expression of lincRNA-COX2 in the microglia. Previous studies (Carpenter et al.,
2013; Hu et al., 2016a) have demonstrated that lincRNACox2 as an early-primary gene
was under controlled by NF-kB signaling in macrophages and microglia. The next question
is whether and how morphine-ADEVs regulate NF-kB signaling in the microglia. Based on
the findings that cellular miRNA (with high GU motif, such as let-7) can activate TLR7/ NFkB signaling pathway, suggesting thereby novel inflammatory potential for miRNAs
(Lehmann et al., 2012). We rationalized that morphine-ADEVs that abundantly carried a
lot of miRNA-cargoes could have the potential to bind with TLR7 (an endosomal TLR) to
initiate activation of TLR7/ NF-kB pathway, which, in turn, leads to induction of lincRNACOX2 expression. For this, we first to check whether ADEVs could reach endosomes.
Mouse primary microglia were incubated 30 min with ADEVs isolated from mouse primary
astrocyte that transfected with a plasmid of TSG101 (exosomal marker) fused with
mCherry, followed by fixing the microglia for checking localization of ADEVs with
endosomes. Fixed microglia were stained EEA1 (endosomal marker) and also assessed
mCherry-TSG101-tagged ADEVs using confocal microscopy. As shown in Figure 6B, we
found mCherry-TSG101-tagged ADEVs co-localized with the microglial endosomal
marker EEA1, indicating ADEVs can be taken up by the microglia and further reach to the
endosome.
Furthermore, we next sought to investigate whether ADEV-miRNAs contained AUor GU-motif that could also serve as TLR7/8 RNA agonists. For this, we isolated ADEVs
from either control or morphine-exposed astrocytes culture media and extract the RNAs
from ADEVs. The purified RNAs were used for RNA-sequencing (RNA-seq) analysis. As
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shown in figure 6A, we found there were 15 of 4-mer AU- or GU- motif-containing miRNAs
significantly upregulated and, 9 of

4-mer AU- or GU- motif-containing miRNAs

downregulated in morphine-ADEVs compared with the control-ADEVs. Additionally, we
selected several miRNAs identified from the RNAseq data for further validation using
qPCR (Figure 6C). Intriguingly, from the RNA-seq data, the total reads of miRNAs in
morphine-ADEVs were significantly increased compared with that in control-ADEVs.
Given those findings indicate thereby that morphine-ADEVs could induce increased
activation of TLR7/8 signal pathway in the recipient microglia compared with controlADVEs.
Next, we sought to investigate the downstream signaling of the TLR7/8 pathway,
whether morphine-ADEVs induce activation of NF- kB in the microglia. Exposure of either
control- or morphine-ADEVs to mouse primary microglia for 30 min, followed by
immunocytochemistry to check nuclear translocation of NF- kB p65. As shown in Figure
7A, exposure of morphine-ADVEs to microglial cells significantly resulted in increased the
nuclear-translocation of NF-kB p65 compared with microglia exposed to control-ADEVs.
Intriguingly, we use TLR7 KO microglia to further confirm morphine-ADEVs-mediated
activation of NF- kB involved in TLR7. As expected, morphine-ADEVs failed to induce
nuclear translocation of NF- kB p65 in TLR7 knockout (KO) microglial cells (Figure 7B).
To further investigate morphine-ADEV-mediated translocation of NF-kB via ADEV-miRs
cargoes activate the TLR pathway. Mouse primary astrocytes with either control or DicersiRNA for 24 hrs, and subsequently exposed them to morphine for another 24 hrs.
Exposure of either control-ADEVs or morphine-ADEVs to either wildtype (WT) or TLR7
KO-mouse microglia for 30 min, followed by harvesting the cells for detection of nuclear
translocation of the NF-kB p65 subunit using both western blotting and fluorescent
immunostaining. As shown in Figures 7C–F, Morphine-ADEVs isolated from Dicer KO
astrocytes failed to induce nuclear translocation of NF-kB p65 in WT microglia. These data
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thus underpin miRNAs cargo of the morphine-ADEVs play a pivotal role in the activation
of the TLR7-NF-kB signaling pathway.
We have demonstrated that morphine-ADEVs could be taken up and reach the
endosome of recipient microglia that triggers the activation of the TLR7/NF-κB pathway.
Herein we sought whether morphine-ADEVs could regulate expression of lincRNA-Cox2
(an NF-κB regulating non-coding RNA) in the microglia. To explore this thinking, exposure
of mouse primary microglia to either SC-514 (NF-kB inhibitor) or chloroquine (TLR7
inhibitor) for 1h, followed by exposure of the microglia to either control- or morphineADEVs for another 4 hrs. Sequentially, we checked the expression of lincRNA-Cox2 using
real-time PCR. As shown in Figure 8A, exposure of microglia to morphine-ADEVs resulted
in a significant induction of lincRNA-Cox2 compared with microglia exposed to controlADEVs. However, in the group of NF- kB inhibition (SC-514) or TLR 7 inhibition
(chloroquine), morphine-ADEVs failed to upregulate the expression of lincRNA-Cox2.
To further validate the TLR7 pathway involving in morphine-ADEVs-mediated
induction of lincRNA-Cox2, either C57BL/6N WT or TLR7 KO mice were used for mouse
primary microglia cultured, and those primary microglia were exposed to either control- or
morphine-ADEVs. After the stimulation, we performed RT-PCR to assess the expression
of lincRNA-Cox2. As shown in Figure 8B, exposure of morphine-ADEVs resulted in the
induction of lincRNA-Cox2 in WT microglia. However, morphine-ADEVs failed to induce
expression of lincRNA-Cox2 in TLR7 KO microglial cells.
Next, to determine what is the mechanism by which lincRNA-Cox2 regulates
phagocytosis-related genes. RNA fluorescent in situ hybridization (FISH) was used to
check the action site of lincRNA-Cox2 in microglia. The FISH analysis demonstrated the
expression of lincRNA-Cox2 located at nuclear, perinuclear, as well as cytoplasmic in
microglial cells (Figure 8C). Further validation of these findings, we extracted RNAs from
different subcellular fractions of microglia, followed an assessment of the expression of
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lincRNA-Cox2 using real-time PCR. As shown in Figure 8D, the expression of
lincRNACox2 predominantly located at the nucleus in the microglia, cytosol mRNA
GAPDH located at the cytosol and U1 small nuclear RNA (snRNA) was, as expected,
confined to the nucleus. Our finds were consistent with previous studies (Hu et al., 2016a),
herein, our results indicated that lincRNA-Cox2 could play an essential role in regulating
the expression of other genes (such as phagocytosis-related genes) at the transcription
level in microglia.
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Figure 6 ADEVs are internalized by microglial cells and localize to late
endosomes.
(A) Heatmap of the expression profile of AU- and GU-rich miRNAs in EVs from
control and morphine-stimulated human primary astrocytes. (B) Mouse primary microglial
cells were incubated with ADEVs purified from pEF6.mCherry TSG101-transfected mouse
primary astrocytes for 20 min. Paraformaldehyde fixed microglial cells were permeabilized
and stained for EEA1, followed by FITC-conjugated secondary antibody and visualized by
fluorescence microscopy. Scale bars, 10 mm. (C) qPCR validation of representative
differentially expressed miRNAs identified from the RNA-seq. All experiments were done
at least three independent times. *p < 0.05 versus control.
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Figure 7 ADEVs released from morphine-exposed astrocytes induce nuclear translocation
of NF-kB.
(A and B) Wild-type (A) and TLR7 KO (B) mouse primary microglial cells were
treated with EVs (2 mg of EVs per 2*10^5 cells) isolated from morphine-exposed
astrocytes for 30 min. The subcellular localization of endogenous p65 was visualized by
indirect immunofluorescence using anti-p65 antibodies (green). Nuclear DNA was
revealed by DAPI staining. Scale bars, 50 mm. (C and D) Primary mouse astrocytes were
transfected with either control or Dicer-siRNA for 24 hr, followed by morphine exposure
for 24 hr. Wildtype (C) and TLR7 KO (D) mouse microglial cells were exposed to EVs (30
min) isolated from astrocyte conditioned media followed by detection of NF-kB p65 in the
nuclear fraction by western blot. (E) All experiments were done at least three independent
times. Band intensities of the cytoplasmic and nuclear extractswere quantified and
normalized against b-actin and histone H3, respectively, and compared with untreated

52
cells. (F) Wildtype mouse primary microglial cells were treated with indicated ADEVs for
30 min. Subcellular localization of endogenous p65 was visualized by indirect
immunofluorescence using anti-p65 antibodies (green). Nuclear DNA was revealed by
DAPI staining. Scale bar=20 μm. All data are presented as mean ± SD. *p < 0.05 versus
control using Student’s t-test.
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Figure 8 Morphine-ADEV-mediated induction of lincRNA-Cox2 involves TLR7 and NFkB.
(A) Mouse primary microglial cells were pre-treated with either TLR7 inhibitor
(chloroquine 25 mM) or NF-kB inhibitor (SC-514, 5 mM) for 1 hr, followed by exposure of
cells for 4 hr to EVs (2 mg of EVs per 2 105 cells) isolated from astrocyte conditioned
media. Total RNA isolated from cells was analyzed by real-time PCR for expression of
lincRNACox2. (B) Mouse primary microglial cells were isolated from wild-type and TLR7
KO pups and exposed to EVs isolated from morphine-stimulated astrocyte conditioned
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media for 4 hr. Total RNA from cells was analyzed by real-time PCR for the expression of
lincRNA-Cox2. (C) Representative confocal images of ISH assay using a probe specific
for lincRNA-Cox2 (red) combined with DAPI staining (blue) and immunostaining for
GAPDH (green) in mouse primary microglia. Scale bar, 10 mm. (D) Subcellular
fractionation followed by qPCR for lincRNA-Cox2, U1 snRNA, and GAPDH mRNA. All
values are shown as the mean ± SEM. *p < 0.05 versus control; #p < 0.05 versus treatment.
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7. Protective role of knockdown of lincRNA-Cox2 in morphine-mediated impaired
phagocytic activity in vivo.
Having determined the mechanism by which morphine-ADVEs activate
TLR7/NFκB/LincRNA-Cox2 axis to induce impaired microglial phagocytotic activity in vitro.
In consideration of lincRNA-Cox2 is the critical player underline this mechanism, we next
sought to explore whether knockdown of lincRNA-Cox2 could alleviate impaired microglial
phagocytic activity in mice-administrated with morphine. In the filed targeting therapeutic
drugs to the CNS is still a major challenge. Recently the EVs are showing potential to be
as promising vehicles for the drug delivery through the BBB according to their
bioavailability and innate biological nature. EVs intranasal administration has been
considered as a preferred noninvasive method that could help transport EV-loaded drug(s)
to the brain (Alvarez-Erviti et al., 2011; Zhuang et al., 2011). According to that knowledge,
we plan to examine whether ADEVs-loaded siRNA-LincRNA-Cox2 intranasally give to
mice could restore morphine-mediated impaired phagocytotic activity. First of all, the
biodistribution of intranasally administered EVs was checked to make sure the ADEVsloaded siRNA could be delivered to the brain. For this, PKH26-dye-labeled EVs were
intranasally given to WT mice. After 4 or 24 hrs later, the animals were transcardially
perfused with ice-cold PBS, followed by harvesting tissues for assessment of ADEVs
biodistribution using the in vivo imaging system (IVIS). As shown in Figure 9A, we detected
the signal of labeled EVs in the lungs, brain, gut, liver, and heart in 4 hrs EV-administrated
mice. Intriguingly, in 24-hrs post-EV administration mice, we only detected the signal of
labeled EVs in the brain and heart other than other tissues (lungs and the gut). Next, we
sought to check whether microglial cells took up the labeled ADEVs in vivo. We did
immunohistochemistry for Iba-1(microglial marker) that to check the co-localization of
PKH26+ ADEVs with Iba1+ cells. As shown in Figure 9B,we found microglia (green) do
take up labeled-ADEVs (red).
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In the next logic step, we sought to assess the knockdown efficacy of the lincRNACox2 siRNA-loaded ADEVs in vivo. For this, WT mice were intraperitoneally injected with
either saline or morphine (10 mg/kg, twice/day) for five consecutive days. Simultaneously,
1 hr prior to mice were injected either morphine or saline, either control or lincRNA-Cox2
siRNA-loaded ADEVs (20 mg/time) were intranasally administrated to these two groups
of mice (saline or morphine group). On day 5, one hour after the last either saline or
morphine injection, mice were sacrificed, followed sorting out adult microglia and
assessment of lincRNA-Cox2 using real-time PCR. As shown in Figure 9C, morphineinjection significantly induced the upregulation of lincRNA-Cox2 in isolated adult microglia
compared with its expression in microglia isolated from the saline-injected controls. In
addition, we found ADEVs-loaded lincRNA-Cox2 siRNA successfully knockdown of its
expression in microglia sorted out form either saline or morphine-administrated mice.
In the next step, we performed ex vivo phagocytosis assay on the brain slices. Two
groups of mice (saline or morphine-administrated) were intranasally given either controlsiRNA- or lincRNA-Cox2-siRNA-loaded ADEVs. On the Day5, the mice brian were cut into
130 μm thick slices. The live brain slices were incubated with fluorescent-beads for 1h,
followed washing and fixing of the slices and sequentially to be immunostained for Iba1
(microglial marker). As shown in Figures 9D and 9E, fewer fluorescent beads
phagocytosed by microglia in the morphine-administrated group compared with salineinjected controls, suggesting thereby that morphine administration resulted in impaired
microglial phagocytosis in vivo. Intriguingly, intranasal delivery of lincRNA-Cox2 siRNAloaded ADEVs successfully restored microglial phagocytic activity in morphineadministrated mice compared with the morphine-administered mice that were
administrated with control siRNA-loaded ADEVs.
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Figure 9 Knockdown of lincrna-cox2 ameliorates morphine-mediated impairment of the
phagocytic activity of microglia in vivo.
(A) PKH26-labeled EVs (20 mg) were intranasally delivered to WT mice (n = 3).
Mice were sacrificed 4 and 24 hr posttreatment, and the harvested organs were imaged
using a Xenogen IVIS 200 imager. A scale of the radiance efficiency is presented on the
right. (B) Immunostaining of the brain sections of mice administered PKH26-labeled EVs
for the microglial marker Iba1 (green). Representative micrographs are shown (original
magnification 20). Scale bar, 100 mm. (C) Real-time PCR for lincRNA-Cox2 in the
CD11b+/CD45+ dim population of microglia sorted from the brains of various groups of
mice. (D) Representative micrograph of brain slices (from 8-week-old mice) incubated with
fluorescent beads (green). Scale bar, 20 mm. (E) Quantification of the number of Iba1positive (red) microglia (with phagocytosed beads) normalized to the total number of Iba1positive cells. n = 20 fields of view from three mice. All data are presented as mean ± SD;
*p < 0.05 versus saline/si-control group; #p < 0.05 versus morphine/si-control group using
Student’s t test.
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Figure 10 Intranasal delivery of morphine-ADEVs increased the expression of lincRNACox2 in microglia.
(A) ADEVs were isolated from either control or morphine stimulated mouse primary
astrocytes and subsequently intranasally delivered to WT mice (n=3). Twenty-four hours
later, mice were subjected to transcranial perfusion with ice-cold PBS. Brains were
harvested for detection of lincRNA-Cox2 by ISH and immunostaining for Iba1. Scale
bar=20 μm. (B) qPCR of lincRNA-Cox2 in microglia sorted from ADEV-administered mice.
* P < 0.05 vs control-ADEV / morphine-ADEV group. All values are shown as the mean ±
SEM.
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8. Discussion
EVs related miR, one of the most well-studied biology components in EVs, played
a critical role in cell-to-cell communication and acted as pathogenesis factors resulting in
impairment of cellular function in various diseases, including CNS disease (Hu et al., 2012;
Konadu et al., 2015; Roth et al., 2015; Tang et al., 2016). For example, we have previously
shown both HV Tat and morphine induce upregulation of miR-29b in ADEV, which, in turn,
take up by neurons leads to downregulation of PDGF-BB that result in neuronal death. In
addition, a study from another group, Yelamanchili et al. demonstrated that HIV infection
resulting in increased induction of blood macrophage-derived EV-miR-21 triggers
activation of the TLR7-dependent downstream necroptosis pathway (Yelamanchili et al.,
2015). However, the role of EV-miR in opioids abuse remains largely unknown. Intriguingly,
the data of our RNAseq profiling of morphine-ADEVs demonstrating AU-or GU-motif
riched miRNAs highly accumulated in the ADEVs, indicating morphine-ADEVs could direct
activate TLR7 signaling pathway. And this is in keeping with published reports on the role
of EV miRNAs in this process (Fabbri et al., 2012; Lehmann et al., 2012). However, EVmiR-mediated activation of TLR7 to regulate expression of lincRNA, further to regulate
cellular function remains poorly understood. In our current study, we reveal a novel role of
lincRNA-Cox2 in regulating microglial phagocytosis by controlling the expression of a set
of phagocytosis-related genes. We have demonstrated that exposure of mouse microglial
cells to morphine-ADEVs resulted in impaired phagocytic function involving the TLR7-NFkB-lincRNA-Cox2 axis. To validate whether morphine-ADEVs induced expression of
lincRNA-Cox2 in vivo. The WT mice were intranasally given either control-ADEVs or
morphine-ADEVs. Sequentially, we performed double in situ hybridization (ISH) for
lincRNA-Cox2 with immunostaining for Iba1 in the brain sections that assessed for the
expression of lincRNACox2. Additionally, mouse adult microglia were also sorted out
using flow cytometry from the mice brains, followed by an assessment of lincRNA-Cox2
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expression using real-time PCR. As shown in figure 10A & 10B, the intranasal delivery of
morphine-ADEVs resulted in the induction of lincRNA-Cox2 in microglia in vivo. In our
study, we provided a novel mechanism by which ADEVs-miRNA cargoes activate the
TLR7-NF-kB pathway to regulate expression of lincRNA-Cox2 in microglia. Besides that,
we also have to mention miRNA-cargo also can regulate cellular function via miRNAmRNA interaction in the recipient cells. Future IPA (Ingenuity Pathway Analysis)
bioinformatic analysis is needed to understand the complex regulatory networks in the
context of morphine-ADEVs-mediated the dysregulation of miRNAs. Our future efforts will
focus on restoring the morphine-ADEVs-mediated dysregulation of miRNAs in the
microarray screen, which, in turn, could further help understand a link between the
ADEV/TLR7/8/NF-kB and lincRNA-Cox2 pathway in the context of microglial phagocytosis.
Microglial phagocytotic activity plays an essential role in the maintenance of tissue
homeostasis via rapid clearance of apoptotic cells, cells debris, pathogens, and other
insults, which, in turn, lead to the elimination of immunogens as well as prevention or
resolution of inflammation (Arandjelovic and Ravichandran, 2015). The elegant studies
were done by Ninković et al., they demonstrated exposure of morphine resulted in
impairment of bacterial phagocytosis by macrophages (Ninkovic and Roy, 2012). The
further mechanism study showed this effect was opioid receptors- dependent induced
inhibition of actin polymerization and pathogen internalization. Intriguingly, Jung-Hee Ryu
et al. did another study., they found morphine could reduce LPS-mediated microglial
phagocytosis via opioid receptor-dependent P38 MAPK inhibition (Ryu et al., 2018).
According to these findings, thus suggested that the morphine-mediated suppression of
macrophage/microglial phagocytosis and pathogen clearance, which, in turn, lead to
worsening of disease pathogenesis. In our current study, there were 20 phagocytosisrelated genes identified to be regulated by lincRNA-Cox2. And there were 15 out of 20
genes negatively regulated by the lincRNA-Cox2, indicating lincRNA-Cox2 could inhibit
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the microglial phagocytotic activity. Further, we performed in vitro and ex vivo
phagocytosis assay to demonstrate a novel function of lincRNA-Cox2 that of inhibiting
microglial phagocytosis.
In other studies LincRNA-Cox2 has been demonstrated as an essential mediator
for controlling inflammatory responses in both microglia and macrophages (Elling et al.,
2018; Hu et al., 2016a; Xue et al., 2019). Now our new findings showed its inhibitory role
in microglial phagocytosis that could be a new target for therapeutics. Thus, we thought
knockdown of lincRNA-Cox2 could be another therapeutic strategy focused on improving
microglial phagocytic function and alleviating neuroinflammation associated with opiate
abuse.
Gene therapy attracted a lot of attention due to its potential as a promising tool for
the treatment of human diseases that failed to be cured by conventional therapies. In fact,
siRNAs as the therapeutic reagents can be loaded into the EVs to achieve the effect of
antiinflammation in the CNS. The group of Lydia Alvarez-Erviti et al. firstly development a
method to deliver siRNA via EV selectively into the CNS. The engineered dendritic cells
are made to express an exosomal membrane protein Lamp2b fused to the neuron-specific
RVG peptide3 that achieve targeting selectively in the CNS. Further, they used this
engineered exosome to carrier siRNA-BACE1 and successfully knocked down mRNA
(60%) and protein (62%) of BACE1 in the WT type mice (Alvarez-Erviti et al., 2011). Our
in vivo study, the first time clearly demonstrated that intranasal delivery of lincRNA-Cox2
siRNA to the brain of morphine-administrated mice that could successfully restore the
morphine-mediated impaired microglial phagocytosis. In addition, we use the same
strategy that delivers lincRNA-Cox2-siRNA via ADEVs that taken up by microglia, which,
in turn, restore LPS-induced lincRNA-Cox2 expression and microglial proliferation in LPSadministered mice.
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In conclusion, our findings suggest that a novel mechanism by which morphineADEVs result in impaired phagocytic function via its effect on the activation of TLR7-NFkB-lincRNA-Cox2 axis. Importantly, we also successfully to develop a therapeutic strategy
of delivering lincRNA-COX2-siRNA via ADEVs to knock down lincRNA-Cox2 that achieve
successfully restoring morphine-impaired phagocytic activity in microglia in vivo. Our
findings have ramifications for the development of EV-loaded RNA drug target(s) as
therapeutics for a multitude of CNS disorders involving microglial deficits associated with
opiate abuse-mediated neuroinflammation.
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CHAPTER IV

THE ROLE OF ADEVS IN MORPHINEMEDIATED MICROGLIAL
ACTIVATION: IMPLICATION FOR
NEUROINFLAMMATION
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9. Morphine-mediated microglial morphological change and activation in vivo
The morphologies of microglia are closely related to their function and activation
status. Here, we sought to determine morphine-mediated microglial activation by
examining the Iba-1 expression and microglial morphological change. C57BL/6N mice
were injected with morphine (10 mg/kg) twice a day for five consecutive days, followed by
an assessment of microglial marker Iba1 expression level by western blot and examination
of the microglial morphological changes by immunostaining with Iba1 in various brain
regions (cortex, hippocampus, thalamus, and striatum). The Iba-1 expression was
significantly upregulated in the thalamus (Figure. 11A), but not in other regions (Figure
11D & Figure 12A & D) of mice administrated morphine compared with the saline group.
The fractal dimension (D), which determines the complexity of the pattern was found
significantly decreased in the thalamus (Figure 11C), but not other regions (Figure 11F &
Figure 12C & F) of mice administrated morphine compared with the saline group. The
density of cells which also called the parameter solidity was significantly increased in the
thalamus (Figure 11C), but not other regions (Figure 11F & Figure 12C & F) of mice
administrated morphine compared with the saline group. The area of cells was significantly
decreased in the thalamus (Figure 11C), striatum (Figure 11F), cortex (Figure 12C), but
not hippocampus (Figure 12F) of mice administrated morphine compared with the saline
group. Perimeter which measures the single outline of cell shape was found significantly
decreased in the thalamus (Figure 11C), striatum (Figure 11F), but not cortex (Figure 12C)
and hippocampus (Figure12F) of mice administrated morphine compared with the saline
group. Span ratio which measures the ratio of the major over the minor axes of the convex
hull was not significantly changed in all the regions, as well as the lacunarity which
associated with changes in the soma and additional morphological features(FernandezArjona et al., 2017) were only found significantly changed in the striatum area (Figure 12C).
To further examine the effects of morphine on microglial activation in vivo, adult microglia
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cells from mice administrated saline or morphine were also isolated by Percoll gradient
centrifugation and sorted by labeling with CD11b and CD45 using Flow cytometry.
CD11bhighCD45low microglia cells were collected and assessed for expression of IL-6/TNFa
by real-time PCR. As shown in Figure 11G & H, IL-6/TNFa were significantly increased in
the adult microglia isolated from mice administrated with morphine compared with the
saline group.
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Figure 11 Effect of morphine on microglial activation in thalamus and striatum region.
(A) Representative Western blot and quantification of Iba1 in thalamus lysates from
mice administrated saline or morphine (n=4 / group). (B) Representative images of Iba-1+
cells and its pairwise outline shape were used for morphological parameters measures in
the thalamus of mice administrated saline or morphine. (C) Quantification of morphological
parameters fractal dimension, density, area, perimeter, span ratio, lacunarity in the
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thalamus of mice administrated saline or morphine. (D) Representative Western blot and
quantification of Iba1 in striatum lysates from mice administrated saline or morphine. (E)
Representative images of Iba-1+ cells and its pairwise outline shape were used for
morphological parameters measures in the striatum of mice administrated saline or
morphine. (F) Quantification of morphological parameters fractal dimension, density, area,
perimeter, span ratio, lacunarity in the thalamus of mice administrated saline or morphine.
(G) The real-time PCR analysis of TNF-α mRNA expression in adult microglial cells
isolated from the brain of mice administrated saline or morphine. All date are presented
as mean ± SD or SEM of three or four individual experiments. *, P < 0.05; **, P < 0.01; ***,
P < 0.001 versus saline group using Student’s t-test.
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Figure 12 Effect of morphine on microglial activation in the cortex and hippocampus region.
(A) Representative Western blot and quantification of Iba1 in cortex lysates from
mice administrated saline or morphine (n=4 / group). (B) Representative images of Iba-1+
cells and its pairwise outline shape were used for morphological parameters measures in
the cortex of mice administrated saline or morphine. (C) Quantification of morphological
parameters fractal dimension, density, area, perimeter, span ratio, lacunarity in the cortex
of mice administrated saline or morphine. (D) Representative Western blot and
quantification of Iba1 in hippocampus lysates from mice administrated saline or morphine.
(E) Representative images of Iba-1+ cells and its pairwise outline shape were used for
morphological parameters measures in the hippocampus of mice administrated saline or
morphine. (F) Quantification of morphological parameters fractal dimension, density, area,
perimeter, span ratio, lacunarity in the hippocampus of mice administrated saline or
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morphine. All date are presented as mean ± SD or SEM of three or four individual
experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus saline group using Student’s
t-test.
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10. Morphine induces up-regulation of miR-138 in ADEVs involves mu receptor
The role of EVs (containing miRNAs, mRNAs, pro-peptides and cytosolic proteins)
on cell communication has gained prominence this decade (Tkach and Thery, 2016).
Astrocytes were shown to modulate microglial activation and phenotypes via astrocytesderived factors during neuroinflammation have been reported by various studies (Bi et al.,
2013; Jha et al., 2019; Lee et al., 2009; Tripathi et al., 2017). Here, we sought to explore
the role of astrocyte-derived EV (ADEV) in morphine-mediated microglial activation. First,
EVs were isolated from various types of stimulated astrocyte (mouse primary astrocyte,
A172 astrocyte, human primary astrocyte) conditioned media (CM) and assessed for the
characterization. As shown in Figure 13A & C & E, immunoblotting of the lysates from
various centrifugation steps (1000 g, 10,000 g, 100,000 g pellets) revealed the presence
of exosomal markers TSG101, CD63, and Alix in the EV lysates (100,000 g pellet).
Meanwhile, calnexin was examined to check contamination with cell debris in ADEVs
which barely show signal in the EV lysates. Furthermore, Nanoparticle analysis using the
ZetaView revealed a reasonable yield of EVs of the expected size (~100nm; Figure 13B
& D & F). Also, the AFM image clearly demonstrates the isolated EVs are of the diameter
size of 40-100nm (Figure 13G).
To explore the effect of ADEV on microglia, we first sought to examine whether
ADEV could be taken up by microglia. Here, mouse primary microglia (MPM) were
cultured with ADEVs isolated from mouse primary astrocytes that were transfected with a
plasmid encoding the exosomal marker TSG101 fused with mCherry, followed by the
immunostaining of microglial marker Iba1. As shown in Figure 14A, EVs-TSG101-mCherry
were able to reach into the microglial cells in 30 mins. TLR7, a single-stranded RNA
(ssRNA) sensor in innate immunity located at the endosome, regulates the
neuroinflammation and neurodegeneration (Butchi et al., 2011). In order to assess
whether the EVs-TSG101-mcherry could further reach into the endosome where TLR7
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located, mouse primary microglia were immunostained with the endosomal marker EEA1
after incubated with EVs-TSG101-mcherry for 30 mins. As shown in Figure 14B, ADEVs
were found to co-localize with EEA1 in microglia.
In the previous study, we found 15 of the 4-mer containing miRNAs which function
as TLR7/8 RNA agonists, were significantly upregulated in morphine-ADEVs compared
with control-ADEVs by RNA-sequencing (RNA-seq) analyses, while miR-138 was highest
up-regulated miR (Ye et al., 2018). Here, we sought to examine the miR-138 expression
in ADEVs, and astrocytes responded to morphine exposure. As shown in Figure 15A & B,
there was an increased expression of miR-138 in both ADEVs and mouse primary
astrocytes response to morphine exposure. Interestingly, naltrexone (opioid receptor
antagonist) can block morphine-mediated upregulation of miR-138 expression levels in
the ADEVs from mouse primary astrocyte as well as in the cells (Figure 15A&B) which
indicates the opioids mu receptor involves morphine-mediated upregulation of miR138,
but GW4869 (exosome release inhibitor) only reversed morphine-mediated upregulation
of miR-138 expression levels in ADEVs, but not in cells. A similar phenomenon was found
in the human primary astrocytes (Fig. 15C & D). In situ hybridization (ISH) using the DIG
labeled-miR-138 probe on morphine-treated human primary astrocytes demonstrated
increased expression of miR-138 compared with untreated cultures (Figure 15E), and
pretreatment of Naltrexone reversed morphine-mediated upregulation of miR-138. We
next sought to examine whether morphine-ADEV play roles in microglia activation and if
so, whether opioids mu receptor involves. Briefly, mouse primary astrocytes were
pretreated with Naltrexone (10 µM) for 1 hr followed by exposure of cells to morphine for
another 24 hrs, after which the ADEVs were isolated from the supernatant and added to
the primary mouse microglia with the concentration of 500 EVs / cell. Four hours later, IL6/TNFa mRNA levels were assessed by real-time PCR. As shown in Figure 15F,
morphine-ADEV induced IL-6/TNFa expression levels in microglia, while pretreatment of
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Naltrexone resulted in significant amelioration of morphine-ADEV mediated upregulation
of cytokines expression (TNFa / IL-6).
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Figure 13 Characterization of EVs Isolated from Astrocyte Culture.
(A) Western blot characterization of mouse primary astrocyte EVs with exosome
marker antibody specific for TSG101, CD63, and Alix. Calnexin was used as a control for
cell debris contamination. (B) Size and particle distribution plots of isolated EVs from
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mouse primary astrocyte by NanoSight Tracking Analysis (NTA). The plot shows a peak
size of around 1 nm for isolated EVs. (C) Western blot characterization of A172 astrocyte
EVs with exosome marker antibody specific for TSG101, CD63, and Alix. Calnexin was
used as a control for cell debris contamination. (B) Size and particle distribution plots of
isolated EVs from A172 astrocyte by NanoSight Tracking Analysis (NTA). The plot shows
a peak size of around 1 nm for isolated EVs. (E) Western blot characterization of human
primary astrocyte EVs with exosome marker antibody specific for TSG101, CD63, and Alix.
Calnexin was used as a control for cell debris contamination. (F) Size and particle
distribution plots of isolated EVs from human primary astrocyte by NanoSight Tracking
Analysis (NTA). The plot shows a peak size of around 1 nm for isolated EVs. (G)AFM
image of EVs isolated from mouse primary astrocyte culture supernatants.
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Figure 14 EVs are internalized in microglial and reach the endosomes.
Representative fluorescence images of mouse primary microglial cells incubated
with EVs purified from pEF6.mCherry-TSG101-transfected mouse primary astrocytes for
30 min, followed by the immunostaining of microglial marker Iba-1 (A) and late endosome
marker (EEA1). Iba1 (Green), EEA1(Green), EV-TSG101-mCherry (Red). Bars, 50 µm.
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Figure 15 Morphine induced upregulation of miR138 in EVs released from astrocytes
involves the mu receptor.
(A)The real-time PCR analysis of miR138 mRNA expression in EVs isolated from
mouse primary astrocytes pretreated with exosome release inhibitor GW4869 (10µM) or
mu receptor antagonist Naltrexone (10 µM), followed by morphine exposure for additional
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24 hr. One-way ANOVA, followed by Bonferroni’s post hoc test, was used to determine
the statistical significance among multiple groups. (B) The real-time PCR analysis of
miR138 mRNA expression in mouse primary astrocytes pretreated with exosome release
inhibitor GW4869 (10µM) or mu receptor antagonist Naltrexone (10 µM), followed by
morphine exposure for an additional 24 hr. One-way ANOVA followed by Bonferroni’s post
hoc test was used to determine the statistical significance among multiple groups. (C)The
real-time PCR analysis of miR138 mRNA expression in EVs isolated from human primary
astrocytes pretreated with exosome release inhibitor GW4869 (10µM) or mu receptor
antagonist Naltrexone (10 µM), followed by morphine exposure for additional 24 hr. Oneway ANOVA followed by Bonferroni’s post hoc test was used to determine the statistical
significance among multiple groups. (D)The real-time PCR analysis of miR138 mRNA
expression in human primary astrocytes pretreated with exosome release inhibitor
GW4869 (10µM) or mu receptor antagonist Naltrexone (10 µM), followed by morphine
exposure for an additional 24 hr. One-way ANOVA followed by Bonferroni’s post hoc test
was used to determine the statistical significance among multiple groups. (E)
Representative images of ISH assay using a probe specific for miR-138 (red) combined
with immunostaining for astrocyte marker GFAP (green) in human primary microglia.
Scale bar, 10 µm. (F) The real-time PCR analysis of IL-6 / TNFα mRNA expression in
mouse primary microglia exposed to Mor-ADEV isolated from astrocytes pretreated with
mu receptor antagonist Naltrexone (10 µM), followed by morphine exposure for an
additional 24 hr. One-way ANOVA followed by Bonferroni’s post hoc test was used to
determine the statistical significance among multiple groups. All date are presented as
mean ± SD or SEM of three or four individual experiments. *, P < 0.05; **, P < 0.01; ***, P
< 0.001 versus control group.
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11. ADEV miR-138 interacts with murine TLR7 in the endosomes
Based on the findings that cellular miRNA, let-7, can activate TLR7, suggesting
thereby novel inflammatory potential for miRNAs (Lehmann et al., 2012), we rationalized
that miR-138, that is abundantly expressed in the CNS (Bak et al., 2008; Siegel et al.,
2009) and that has a GU motif for potentially binding TLR7, could also interact with TLR7,
an endosomal TLR. However, before testing the interaction, we first sought to examine
whether ADEV-miR138 could reach endosome, and if so, whether ADEV-miR138 colocalize with TLR7. Briefly, ADEVs were loaded with cy5 labeled miR-138 using Exo-Fect
transfection kit and added to mouse primary microglial cells for 30 min followed by
immunostaining of endosomal marker EEA1. As shown in Figure 16A, there was
colocalization of ADEV-Cy5-miR138 and endosome marker EEA1. While, in the absence
of ADEVs, Cy5-miR138 which also processed by the Exo-Fect transfection kit were not
present in the microglia. Moreover, the ADEVs loaded with miRNA control were performed
as a negative control. Thus, we demonstrated that ADEVs containing miR138 could be
taken up and reach the microglial endosomal compartment. Next, we sought to examine
whether ADEV-Cy5-miR138 colocalizes with TLR7. Similarly, mouse primary microglial
cells were immunostained with TLR7 after EVs-cy5-miR-138 exposure. As shown in
Figure 16B, there was colocalization of ADEV-Cy5-miR138 and TLR7 which indicates that
miR138 could interact with TLR7. At the same time, Cy5-miR138 without ADEVs and the
ADEVs loaded with miRNA control were performed as the negative control.
The next logical step was to examine the binding of miR-138 to endosomal TLR7
by RNA immunoprecipitation (RIP) assay. TLR7 was immunoprecipitated using antibody
specific to TLR7 from BV2 cells lysates followed by an assessment of miR138 expression
in the immunoprecipitates by real-time PCR. As shown in Figure 16C, miR-138 was highly
enriched in the TLR7 co-immunoprecipitated complex compared with the IgG control. To
further confirm these data, HEK-TLR7 cells were used to examine the association of miR-
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138 with TLR7, and miR-138 was found highly enriched in the TLR7 coimmunoprecipitated complex in HEK-TLR7 cells compared with the HEK-Null cells (Figure
16D). Furthermore, biotin-labeled miR138 were transfected into the BV2 cells, followed by
immunoprecipitation with Streptavidin agarose beads. As shown in Figure 16E, the
amount of TLR7 in the miR-138-biotin-immunoprecipitated complex was increased
compared with miR-mut-138-biotin. These findings allude to a possible interaction
between miR-138 and TLR7.
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Figure 16 ADEV miR-138 interacts with murine TLR7 in the endosomes.
(A) Representative fluorescence images of mouse primary microglial cells
incubated with EVs-Cy5-miR138 or EVs-Cy5-mut-miR138 for 30 min, followed by the
immunostaining of (A) late endosome marker (EEA1, Green) and (B) TLR7 (Green).
Cy5-miR138 which also processed by Exo-Fect transfection kit without EVs and EV
loaded with miRNA control were performed as a negative control. Bars, 50 µm. (C)
TLR7 was immunoprecipitated from BV2 cells by IgG / TLR7 antibody, followed by
an assessment of miR138 / U6 expression by real-time PCR. One-way ANOVA
followed by Bonferroni’s post hoc test was used to determine the statistical
significance among multiple groups (D) TLR7 was immunoprecipitated from HEKNull / HEK-TLR7 cells by IgG / TLR7 antibody, followed by an assessment of miR138
expression by real-time PCR. One-way ANOVA followed by Bonferroni’s post hoc
test was used to determine the statistical significance among multiple groups. (E)
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The protein of TLR7 was pulled down by miR-138-biotin / miR-mut-138-biotin with
Streptavidin agarose beads in BV2 cells. All data are presented as mean ± SD or
SEM of three or four individual experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001
versus control group.
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12. ADEV miR-138 induces nuclear translocation of NF-κB p65 through TLR7.
Having determined the binding of miR-138 to TLR7, the next step was to assess
the functionality of this binding. Based on the report that cellular miRNA, let-7 can activate
TLR7 (Lehmann et al., 2012), we rationalized that miR-138 binding to TLR7 could possibly
lead to active the downstream signaling of TLR7 pathway, in particular, NF-kB nuclear
translocation and microglial activation. Herein, Dotap (a liposomal cationic lipid used to
make liposomes to mimic EVs(Fabbri et al., 2012)) was used to encapsulate and directly
deliver miR-138 to BV2 cells. To examine the specificity of miR functionality in the recipient
microglia, it was important to first examine the delivery of miR into these cells. First, BV2
cells were incubated with Dotap mixture of Cy5-miR138 for 30 min followed by the
immunostaining of Iba1, EEA1 and TLR7. Similar to the phenomenon of EV delivery,
Dotap-Cy5-miR138 was found accumulated in the cytoplasm of BV2 cells (Figure 17A) as
well as co-localized with microglial endosome and TLR7 (Figure 17B). Moreover, we
examined the Dotap transfection efficiently by assessment of miR138 levels using realtime PCR and found Dotap-miR138 highly induced miR138 expression levels in the
recipient cells (Figure 17C). Next, we sought to examine the miR138-mediated activation
of NF-kB nuclear translocation which is downstream of the TLR7 pathway in BV2 cells.
Briefly, BV2 cells were exposed to the Dotap-miR138 mixture for various periods of time
(5-180 min) and assessed for the phosphorylation of p65 and translocation of the p65
submit of NF-kB into the nucleus by western blot. Exposure of BV-2 microglia to DotapmiR138 (5 pmol/well) resulted in a time-dependent increase in phosphorylation of the NFkB p65 as well as a time-dependent increase in translocation of the NF-kB p65 subunit in
the nucleus with a concomitant decrease in its expression in the cytoplasm (Figure 17D).
Additional confirmation of these findings by immunostaining also revealed enhanced
translocation of NF-kB into the nucleus in BV2 cells at 15 min after Dotap-miR138
exposure (Figure 17E). To evaluate the role of TLR7 in miR-138 induced NF-kB activation,
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HEK-Blue-TLR7 and HEK-Null cells were exposed to Dotap-miR138 or Dotap-mutmiR138 mixture, followed by measuring the NF-kB driven reporter SEAP activity.
Exposure to the Dotap-miR138 mixture significantly increased the SEAP activity in HEKBlue-TLR7 cells compared to the Dotap-Ctl, but not in HEK-Null Cells. CL264, TLR7 ligand,
served as the positive control, also significantly increased the SEAP activity in HEK-BlueTLR7 cells, not in HEK-Null cells. While there is no significantly change between Dotapmut-miR138 and Dotap-Ctl in both HEK-Blue-TLR7 and HEK-Null cells (Figure 17F).
To examine the effect of ADEV-miR138 on activation of the TLR7 pathway, WT /
TLR7-KO microglial cells were exposed to EV-miR138 mixture or EV-mut-miR138 for 30
mins and followed by the immunostaining of NF-kB. We found enhanced translocation of
NF-kB into the nucleus in WT microglia cells after EV-miR138 exposure compared with
EV-mut-miR138 exposure (Figure 18A). While there is no significant difference in nuclear
translocation in TLR7-KO microglial cells between EV-miR138 and EV-mut-miR138
groups (Figure 18B). Further confirmation was assessed to detect NF-kB nuclear
translocation in nuclear and cytoplasm fraction by western blot. As shown in Figure 18C,
exposure of WT microglial cells to EV-miR138 (5 pmol/well) resulted in an increased NFkB p65 subunit in the nucleus with a concomitant decrease in its expression in the
cytoplasm. While there is no significant difference in nuclear translocation in TLR7-KO
microglial cells between EV-miR138 and EV-mut-miR138 groups (Figure 18D). The
quantification of NF-kB was shown in Figure 18E. Moreover, to evaluate the role of TLR7
in miR-138 induced NF-kB activation, HEK-Blue-TLR7 and HEK-Null cells were exposed
to EV-miR138 or EV-mut-miR138 mixture, followed by measuring the NF-kB driven
reporter SEAP activity. Exposure to EV-miR138 mixture significantly increased the SEAP
activity in HEK-Blue-TLR7 cells compared to the EV-Ctl, but not in HEK-Null Cells. CL264,
TLR7 ligand, served as the positive control, also significantly increased the SEAP activity
in HEK-Blue-TLR7 cells, not in HEK-Null cells. While there is no significantly changes
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between EV-mut-miR138 and EV-Ctl in both HEK-Blue-TLR7 and HEK-Null cells
(Figure.18F).
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Figure 17 Dotap-miR138 mediated NF-kb nuclear translocation in BV2 cells.
Representative fluorescence images of BV2 cells incubated with DOTAP-Cy5miR138 for 30 min, followed by the immunostaining of (A) microglial marker Iba1 (Green)
and (C) late endosome marker EEA1 (Green) and TLR7 (Green). Bars, 50 µm. (B) The
real-time PCR analysis of miR138 mRNA expression in BV2 cells exposed to various
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concentrations of DOTAP-miR138 (2.5, 5, 10 pmol / well). (D) Representative Western
blot of p-NF-κB p65 in the lysates or NF-κB p65 in the nuclear and cytoplasmic lysates
isolated from BV2 cells exposed to DOTAP-miR-138 for various time points (5 min to 3 h).
(E) BV2 cells were exposed to DOTAP-miR-138 or DOTAP-mut-miR-138, followed by
immunostaining with antibodies specific for NF-κB. Bars, 100 µm. White arrows, NF-κB
nuclear-translocated cells. (F) SEAP activity in HEK-Null / HEK-TLR7 cells exposed to
DOTAP-miR-138 or DOTAP-mut-miR-138 or CL264. All data are presented as mean ±
SD or SEM of three or four individual experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001
versus control group.
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Figure 18 ADEV miR-138 induces nuclear translocation of NF-κB p65 through TLR7.
(A) Wide type mouse microglial cells were exposed to EVs-miR-138 or EVs-mutmiR-138, followed by immunostaining with antibodies specific for NF-κB. Bars, XX µm.
White arrows, NF-κB nuclear-translocated cells. (B) TLR7 KO mouse microglial cells were
exposed to EVs-miR-138 or EVs-mut-miR-138, followed by immunostaining with
antibodies specific for NF-κB. Bars, 100 µm. White arrows, NF-κB nuclear-translocated
cells. (C) Representative Western blot of NF-κB p65 in the nuclear and cytoplasmic lysates
isolated from wide type mouse microglial cells exposed to EVs-miR-138 or EVs-mut-miR-

88
138 for 30 mins. (D) Representative Western blot of NF-κB p65 in the nuclear and
cytoplasmic lysates isolated from TLR7 KO mouse microglial cells exposed to EVs-miR138 or EVs-mut-miR-138 for 30 mins. (E) quantification of NF-κB p65 in the nuclear and
cytoplasmic lysates isolated from wide type or TLR7 KO mouse microglial cells exposed
to EVs-miR-138 or EVs-mut-miR-138 for 30 mins. (F) Human primary microglial cells were
exposed to EVs-miR-138 or EVs-mut-miR-138, followed by immunostaining with
antibodies specific for NF-κB. Bars, 100 µm. White arrows, NF-κB nuclear-translocated
cells. (G) SEAP activity in HEK-Null / HEK-TLR7 cells exposed to EVs-miR-138 or EVsmut-miR-138 or CL264. All data are presented as mean ± SD or SEM of three or four
individual experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus control group.
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13. ADEV miR-138 activates microglia via TLR7-NF-kB signaling pathway
We next sought to determine whether Mor-ADEV containing miR138 induces
microglial activation, and if so, whether the TLR7-NF-kB signaling pathway involves. We
first treated BV2 cells with EVs released from either control or morphine-treated astrocytes
(Ctl-ADEV / Mor-ADEV), followed by assessing the expression of IL-6 & TNF-α by realtime PCR. Mor-ADEV resulted in significant increase of IL-6 & TNF-α mRNA expression
compared with Ctl-ADEV (Figure 19A). ssRNA40, as a positive control, which is an HIVderived 20-mer single-stranded oligoribonucleotide with a GU-rich sequence, activated
TLR7 and induced IL-6 & TNF-α mRNA expression. To validate the role of miR138 in
morphine-ADEVs-mediated upregulation of IL-6/TNFa expression levels in microglial cells.
The mouse primary microglial cells were transfected with anti-miR138 inhibitor or negative
control for 24 hr, exposed to morphine-ADEV/ control-ADEV for an additional 4 hr,
followed by the assessment of IL-6/TNFa mRNA expression by real-time PCR. As shown
in Figure 20A, the pre-transfection of anti-miR138 resulted in significant amelioration of
morphine-ADEV-mediated upregulation of IL-6 & TNF-α mRNA expression. These results
indicated that morphine-ADEVs-mediated upregulation of IL-6/TNFa expression involves
miR138.
Next, we sought to examine the direct effect of miR138 on microglial activation,
BV-2 cells were exposed to Dotap-miR138 (5 pmol / well) for 4 hr and assessed for IL-6
& TNFa mRNA expression. Exposure BV-2 cells to Dotap-miR138 resulted in increased
mRNA expression levels of IL-6/TNFa compared to Dotap-Ctl, while Dotap-mut-miR138
failed to induce the IL-6 & TNFa mRNA levels (Figure 19B). Since Dotap-encapsulated
miR138 indicated the direct effect of miR138, we next sought to examine the effect of EVmiR138. As EV lipid layer protects EV-RNA from degradation mediated by RNase
enzymes, RNase treatment of EVs was used to discriminate EV-RNA species from
extracellular RNA not in EVs. To do this, miR138 was first loaded into the ADEV followed

90
by incubation with RNase (ADEV-miR138+RNaseA); in the other way, miR138 were first
incubated with RNase followed by transfection into ADEV (ADEV +RNaseA+miR138).
Later mouse primary microglia were exposed to the ADEV-miR138+RNaseA or ADEV
+RNaseA+miR138 for 4 hr followed by the assessment of IL-6/TNFa by Real-time PCR.
As shown in Figure 20B, ADEV-miR138 incubated with RNase still induced IL-6/TNFa
expression levels in MPMs as expected, while miR138 incubated with RNase before the
transfection was used as negative control which didn’t show any effect on IL-6/TNFa
expression in MPMs.
To examine the specificity of miR-138 binding to TLR7 which leading to microglial
activation, WT/TLR7-KO microglia were treated with Dotap-miR-138 or controls for 4 hr
(Dotap-Ctl, miR-196a lacking the TLR7 binding motif as a negative control, LPS as positive
control), followed by an assessment of IL-6 & TNF-α mRNAs expression. As shown in
Figures 19C&D, exposure WT microglia to Dotap-miR-138 and LPS resulted in a
significant increase of inflammatory cytokine mRNAs expression, while the phenomenon
was not observed in cells exposed to Dotap-miR-196a. Meanwhile, Dotap-miR138 failed
to cause up-regulation of mRNA expression levels of IL-6 / TNFa in TLR7-KO microglial
cells, unlike TLR7-KO microglial cells were exposed to LPS. To further confirm whether
miR-138-mediated induction of IL-6 & TNFa was regulated transcriptionally, WT/TLR7-KO
microglia were treated with Dotap-miR-138 or controls for 24 hr (Dotap-Ctl, miR-196a
lacking the TLR7 binding motif as negative control, LPS as positive control), followed by
collection of the supernatant and assessment of IL-6 & TNF-α protein concentration by
Elisa. As shown in Figures 19E & F, exposure WT microglia to Dotap-miR-138 and LPS
resulted in the up-regulation of inflammatory cytokine release, while the phenomenon was
not observed in cells exposed to Dotap-miR-196a. Meanwhile, Dotap-miR138 failed to
cause up-regulation of IL-6/ TNFa release from TLR7-KO microglial cells, unlike TLR7-KO
microglial cells were exposed to LPS.
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To further investigate whether morphine-ADEV-mediated microglial activation is
attributed to the miRNA cargo in the EVs, mouse primary astrocytes were transfected with
Dicer-siRNA/siRNA Ctl for 24 hr, followed by the morphine exposure for an additional 24
hr. Subsequently, ADEVs were isolated from the conditional media and added to wild-type
(WT) or TLR7-KO mouse microglia cells for 4 hr, followed by the assessment of IL-6/TNFa
expression levels by real-time PCR. Mor-ADEV isolated from siRNA ctl transfected
astrocytes induced IL-6/ TNFa mRNA levels in WT microglia compared with Ctl-ADEV,
however Mor-ADEV isolated from siRNA Dicer transfected astrocytes failed to induced IL6/ TNFa mRNA levels in WT microglia. Furthermore, Mor-ADEV isolated from siRNA-Ctl
transfected astrocytes failed to induce IL-6/ TNFa mRNA levels in TLR7-KO microglia
(Figures 20C & D).
To confirm whether increased IL-6/TNFa mRNA levels manifested as increased
protein translation, ADEVs isolated from siRNA Dicer / siRNA Ctl transfected astrocytes
subsequently with morphine exposure were added to WT/TLR7 KO microglia cells for 24
hr followed by the collection of supernatants that were assessed for expression of secreted
IL-6/TNFa using the ELISA assay. Similar to the Real-time PCR results, Mor-ADEV
isolated from siRNA ctl transfected astrocytes induced IL-6/ TNFa mRNA levels in WT
microglia compared with Ctl-ADEV, while Mor-ADEV isolated from siRNA Dicer
transfected astrocytes failed to induced IL-6/ TNFa mRNA levels in WT microglia (Figures.
20E &G) . Moreover, Mor-ADEV isolated from siRNA-Ctl transfected astrocytes failed to
induce IL-6/ TNFa mRNA levels in TLR7-KO microglia (Figures. 20F &H).
Next, we confirmed our results in the Human primary astrocytes and microglia cells.
Human primary microglial cells were exposed to Mor-ADEV or Ctl-ADEV isolated from
human primary astrocytes which were treated with/without morphine for 24 hr, followed by
the assessment of IL-6/TNFa mRNA expression by real-time PCR. Similarly, Mor-ADEV
induced IL-6/TNFa mRNA expression levels in human primary microglia compared with
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Ctl-ADEV (Figure 20I). To confirm Mor-ADEV mediated upregulation of IL-6/TNFa mRNA
expression also involves the miR-138-TLR7-NF-kB signaling pathway. Human primary
microglial cells were pretreated with chloroquine (TLR7 inhibitor) or SC-514 (NF-kB
inhibitor) for 1h followed by Dotap-miR-138 exposure for an additional 4 hr. As expected,
Dotap-miR138 induced expression of IL-6/TNFa levels, while pretreatment of chloroquine
and SC-514 resulted in abrogation of miR-138-induced up-regulation of IL-6/TNFa mRNA
expression (Figure 19G). Moreover, to apply to EV’s involvement, human primary
microglial cells were pretreated with chloroquine (TLR7 inhibitor) or NF-kB inhibitor (SC514) for 1h followed by EV-miR-138 exposure. Four hours post-exposure, IL-6 and TNFα, were assessed by real-time PCR. As shown in Figs. 20J, miR-138 induced microglial
activation was significantly inhibited by chloroquine and SC-514.
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Figure 19 DOTAP miR-138 activates microglia via the TLR7-NF-kB signaling pathway
ADEV.
(A) The real-time PCR analysis of IL-6 TNF-α in BV-2 cells treated with EVs
isolated from control or morphine treated astrocytes or ssRNA40. (B) Real-time PCR
analysis of IL-6 and TNF-α in BV-2 cells treated with DOTAP formulations of miR-138 and
mutant-miR-138. The real-time PCR analysis of IL6 (C) and TNFα (D) in WT or TLR7 KO
microglial cells exposed to Dotap-miR138, DOTAP-miR196 or LPS. IL6 (E) and TNFα (F)
were assayed by ELISA in supernatants of WT or TLR7 KO microglial cells cultured for 24
h in the absence or presence of Dotap-miR138, DOTAP-miR196 or LPS. (G) Real-time
PCR analysis of IL-6 and TNF-α in human primary microglial cells pretreated with
endosomal TLR inhibitor Chloroquine, IKK-2 inhibitor SC514 for 1 hr, followed by exposure
to DOTAP-miR-138 and DOTAP-mut-miR-138 for additional 4 hr. All data are presented
as mean ± SD or SEM of three or four individual experiments. *, P < 0.05; **, P < 0.01; ***,
P < 0.001 versus control group.
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Figure 20 ADEV miR-138 activates microglia via the TLR7-NF-kB signaling pathway.
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(A) The real-time PCR analysis of IL-6 and TNF-α in mouse primary microglial cells
transfected with anti-miR138 for 24 hr, followed by exposure to Mor-ADEV for an
additional 4hr. (B) The real-time PCR analysis of IL-6 and TNF-α in mouse primary
microglial cells exposed to ADEV-miR138+RNaseA (miR138 was first loaded into the
ADEV followed by the incubation with RNase) or ADEV +RNaseA+miR138 (miR138 was
first incubated with RNase followed by transfection into ADEV). (C) The real-time PCR
analysis of IL6 in WT/ TLR7 KO microglial cells exposed to Ctl-ADEV or mor-ADEV
isolated from mouse primary astrocytes transfected with Dicer-siRNA/siRNA Ctl for 24 hr,
followed by the morphine exposure for an additional 24 hr. (D) The real-time PCR analysis
of TNF-α in WT/ TLR7 KO microglial cells exposed to Ctl-ADEV or mor-ADEV isolated
from mouse primary astrocytes transfected with Dicer-siRNA/siRNA Ctl, followed by the
morphine exposure. IL6 was assayed by ELISA in supernatants of WT (E) or TLR7 KO (F)
microglial cells cultured for 24 h in the absence or presence of Ctl-ADEV or mor-ADEV
isolated from mouse primary astrocytes transfected with Dicer-siRNA/siRNA Ctl, followed
by the morphine exposure. TNF-α was assayed by ELISA in supernatants of WT (G) or
TLR7 KO (H) microglial cells cultured for 24 h in the absence or presence of Ctl-ADEV or
mor-ADEV isolated from mouse primary astrocytes transfected with Dicer-siRNA/siRNA
Ctl, followed by the morphine exposure. (I) The real-time PCR analysis of IL6 / TNF-α in
human primary microglial cells treated with Ctl-EVs / Mor-EVs isolated from human
primary astrocytes exposed to morphine for 24 hr. (J) The real-time PCR analysis of IL6
/ TNF-α in human primary microglial cells pretreated with endosomal TLR inhibitor
Chloroquine, IKK-2 inhibitor SC514 for 1 hr, followed by exposure to EVs-miR-138 and
EVs-mut-miR-138 for additional 4 hr. All data are presented as mean ± SD or SEM of
three or four individual experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus control
group.
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14. Morphine-induced microglial activation via TLR7
As we found a significant increase of Iba-1 expression levels and microglial
morphological changes in the Thalamus area of C57BL/6N mice injected with Morphine,
we next sought to determine whether TLR7 involved in the Iba-1 expression and microglial
morphological changes in the Thalamus of mice. To do so, the WT and TLR7-KO mice
were injected with Morphine (10 mg/kg) twice a day for five consecutive days, followed by
assessing the expression of microglial marker Iba1 by western blot and examine the
microglial morphological changes by immunolabeling with Iba1 in Thalamus. The Iba-1
expression was significantly upregulated in Thalamus (Figure 21A) in WT mice, but not in
TLR7-KO mice administrated with morphine compared with the saline group (Figure 21B).
To compare the microglial morphological changes, the same parameters as previous were
evaluated (Figure 21C). The Fractal dimension, Area, perimeter which was significantly
decreased in Thalamus of WT mice administrated with morphine, showed no significant
differences in TLR7-KO mice administrated with morphine or saline. The density of cells
which was significantly increased in Thalamus of WT mice administrated with morphine,
showed no significant differences in TLR7-KO mice administrated with morphine or saline
(Figure 21D). To further examine the effects of morphine on microglial activation in TLR7
KO mice, adult microglia cells from TLR7 KO mice administrated saline or morphine were
also isolated by Percoll gradient centrifugation and sorted by labeling with CD11b and
CD45 using Flow cytometry. CD11bhighCD45low microglia cells were collected and
assessed for expression of IL-6/TNFa by real-time PCR. As shown in Figure 21E,
morphine failed to induce the IL-6/TNFa expression in the adult microglia isolated from
TLR7 KO mice.

These results indicated that Morphine-induced microglial activation

involves TLR7.
Next, we sought to examine the involvement of EV-miR138 in morphine-mediated
microglial activation in vivo, mice were pretreated with EV-anti-miR138 or negative control
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by intranasal for 1 hr, followed by intranasal delivery of Mor-ADEVs / Ctl-ADEVs isolated
from mouse primary astrocytes exposed with/without morphine once a day for five
consecutive days. One hour after the last intranasal delivery on day 5, mice were sacrificed,
followed by adult microglial isolation and assessment of IL-6/TNFa expression by realtime PCR. As shown in Fig. 21F, IL-6/TNFa were significantly increased in the adult
microglia isolated from mice administrated with Mor-ADEVs compared with Ctl-ADEVs,
while

Mor-ADEVs-anti-miR138

successfully

upregulation of IL-6/TNFa expression.

ameliorated

Mor-ADEVs-mediated

98

+

Figure 21 Morphine-induced microglial activation via TLR7.
(A) Representative Western blot and quantification of Iba1 in thalamus lysates from
WT mice administrated saline or morphine (n=4 / group). (B) Representative Western blot
and quantification of Iba1 in thalamus lysates from TLR7 KO mice administrated saline or
morphine (n=4 / group). (C) Representative images of Iba-1+ cells and its pairwise outline
shape were used for morphological parameters measures in the thalamus of WT / TLR7
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KO mice administrated saline or morphine. (D) Quantification of morphological parameters
fractal dimension, density, area, perimeter, span ratio, lacunarity in the thalamus of WT/
TLR7 KO mice administrated saline or morphine. (E) The real-time PCR analysis of IL-6
/TNFα mRNA expression in adult microglia cells isolated from the brain of TLR7 KO mice
administrated with Morphine. (F)The real-time PCR analysis of IL-6 /TNFα mRNA
expression in adult microglia cells isolated from the brain of mice administrated with EVanti-miR138 followed by Ctl-ADEV/Mor-ADEV. All date are presented as mean ± SD or
SEM of three or four individual experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus
saline group using Student’s t-test.
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15. MiR-138 is upregulated in the EVs from the morphine-dependence macaques’
brain
Here, we first validate the upregulation of miR-138 in the basal ganglia isolated
from the control and morphine administration macaques using the mature miRNA-specific
qPCR. As shown in Figure 22A, and there was an increased expression of miR-138 in the
basal ganglia of morphine-dependent macaques compared with the untreated control
group. Next step, we further validated by in situ hybridizations, the increased expression
of miR-138 in the astrocytes in the brains of morphine-dependent macaques (Figure 22B)
compared untreated controls. In this regard, we isolated EVs from brains of control and
morphine-dependent macaques and characterized EVs by western blots (WB) of the EV
lysates revealed the presence of exosomal markers CD63 & Flotillin (Figure 22C). The
transmission EM image clearly demonstrates the isolated EVs are of the diameter size of
40-100nm (Figure 22D). Finally, we found an elevated level of miR-138 in the EVs isolated
from the brain of morphine-dependent macaques (Figure 22E).
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Figure 22 miR-138 is upregulated in the EVs from the morphine-dependence macaque's
brain.
(A) The real-time PCR analysis of miR-138 expression in the brains of morphinetreated macaques. (B) Representative images of ISH assay using a probe specific for
miR-138 (red) combined with immunostaining for astrocyte marker GFAP (green) in the
brain

of

morphine-treated

macaques.

Scale

bar=100 μm.

(C)

Western

blot

characterization of monkey and rat brain EVs for exosome markers, CD63 and Flotillin.
(D)

The image shows small vesicles of approximately 100 nm in diameter. Scale

bar=100 nm. (E) Number of EVs isolated from control and morphine-exposed human
primary astrocytes. All experiments were done at least three independent times. Data are
shown as mean ± SEM. *p < 0.05 versus control.
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16. Discussion
Drug abuse hastens the progression of HIV infection and exacerbates the
neurological complications associated with the disease (Norman et al., 2009; Tiwari et al.,
2013; Wen et al., 2011). Morphine has been found that induces the activation of astrocytes
and microglia in the CNS, which contributes to accelerating the progression of HAND
(Dutta et al., 2012; El-Hage et al., 2008). EVs related to miRs, one of the most wellstudied biology components in EVs, play a critical role in cell-to-cell communication and
acted as potential biomarkers in various diseases, including CNS diseases (Kanninen et
al., 2016; Selmaj et al., 2017). While the role of EV-miR in opioids abuse still remains
largely unknown. TLRs, were found expressed in most of cell types in CNS, play a crucial
role in initiating host defense responses during various CNS disease, including HIV
infection (Hernandez et al., 2012), Alzheimer’s Disease (Gambuzza et al., 2014),
Parkinson Disease (Dzamko et al., 2017). It has been reported that TLRs signaling also
involved in Morphine-mediated microglial activation which may be a potential mechanism
for the increased prevalence of HAND in HIV infected opioids abusers (Dutta et al., 2012).
Our previously study demonstrated that EVs derived from astrocytes exposed to morphine
can be taken up by microglia and active TLR7 signaling pathway, ultimately resulting in
impaired microglial phagocytosis, while the components in EVs derived from astrocytes
which play a role in TLR7 activation still unclear (Yang et al., 2018). Here, for the first time,
we demonstrated that morphine induced upregulation of miR138 in EVs derived from
astrocytes exposed to morphine, and this effect can be a paracrine effect of astrocytes on
microglia as EVs released from astrocytes treated with morphine can shuttle miR-138,
which can be taken up by microglia leading to microglial activation. In agreement with the
in vitro results, our in vivo data demonstrated increased microglial activation and
morphology changing in the brain thalamus of mice administered with morphine.
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Microglia morphology and functions are closely related, but most of the studies
focused on cytokine release and Iba1 expression for evaluating the microglial activation,
the microglial morphology changes are rarely reported. For the first time, we examined a
set of 6 morphological parameters to evaluate the microglial morphology changes
responded to morphine, including fractal dimension, density, area, perimeter, span ratio,
lacunarity. Out of six, four morphological parameters were found significantly changed in
the thalamus region of WT mice brain responded to morphine, while this phenomenon
was not seen in the TLR7 KO mice responded to morphine.
MicroRNAs (miRs) have emerged as key regulators in almost every cellular
process. In general, miRs control gene expression at the post-transcription level via
regulating target mRNAs degradation or translational repression(Filipowicz et al., 2008).
Intriguingly, single-stranded RNAs have been shown to activate innate cellular TLRs
leading to the generation of inflammatory cytokines and the activation of NF-kB pathways
to mediate inflammatory responses (Zhang et al., 2016). Previously, it has been reported
that certain miRNAs contain “immunostimulatory” G/U rich sequences; specifically, uridine
clusters that define the innate stimulatory activity of RNA (Heil et al., 2004). These
sequences can bind to TLRs and specifically activate TLR7 in mice (Fabbri et al., 2012) &
TLR8 in humans (TLR8 is nonfunctional in mice)(Akira et al., 2001). A recent report
identified extracellular miR let-7, containing a TLR7 binding motif, as a potent activator of
TLR7 signaling in macrophages & microglia (Lehmann et al., 2012). In this study, we
observed the upregulation of miR-138 which contains a TLR7 binding motif, in the BG of
morphine-dependent RMs. Moreover, we demonstrated that morphine mediated release
of miR-138 in the EVs by the astrocytes, that can be taken up by microglia and result in
microglial activation via activation of the TLR7/8 signaling pathway.
Of note, our recent publication demonstrated that EV-miR-9 released from Tatstimulated astrocytes could be taken up by microglia, and inhibited the expression of
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PTEN, via its binding to the 3’UTR seed sequence of the PTEN mRNA, resulting in
induction of microglial migration(Yang et al., 2018). This effective is achieved by the
binding of miRNA and its target’s 3UTR or coding region on mRNA which occurs in the
cytoplasm. However, unlike miR-9, we found in the current study that exposure of
microglia to an extracellular miRs induced microglial activation through intrinsic TLR7
signaling. The essential feature of this signal is the mislocalization of an endogenous RNA,
which gains access to endosomal TLR7.
Our data thus offers novel insights into the vital function of EV miRNAs in mediating
microglial activation, implicating critical roles of miR-138 released from astrocytes
exposed to morphine. The data does not only shed light on the mechanism underlying the
roles of EVs miRNAs on microglial function but also serve as a foundation for future
designing of nanovesicle &/or miRNA-based therapeutics for the treatment of cognitive
decline observed in HIV-infected opiate abusers.
To this end, how microglia take up EV miRNAs could affect the mechanism in
which they affect the receipt cells. Microglia can take up EVs by either phagocytosis or
membrane fusion and release EV contents into the receipt cells (Hu et al., 2016b;
McKelvey et al., 2015). In our cases, phagocytosis of EV miRNA might be necessary to
activate the endosomal TLR7 pathway. However, Microglia could also take up EV miRNAs
into the cytoplasm, where the EV miRNA binding its target’s 3UTR and exert its function.
The functional implication of morphine-mediated induction of EV miR-138 was also
assessed in an in vivo model. Intranasal delivery of anti-miR138 into mice administrated
with Morphine-ADEV, resulted in the restoration of Morphine-ADEV mediated microglial
activation, thus validating the role of EV miR-138 in microglial activation. These findings
are in agreement with the recent studies implicating the role of EV miRNAs as mediators
of cell activation (Bian et al., 2019; Chaudhuri et al., 2018; Vu et al., 2019).
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In summary, our findings demonstrate a novel molecular pathway of morphinemediated induction of microglial activation, involving the release of miRNA and uptake of
EV by microglia and activation of endosomal TLR7. These findings have implications for
HIV-1-infected heroin abusers that are known to have an increased risk of
neuroinflammation.
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CHAPTER V
THE ROLE OF ADEVS IN
MORPHINE-MEDIATED LOSS OF
PERICYTE COVERAGE ON THE
BBB AND INFLUX OF MONOCYTE:
IMPLICATION FOR
NEUROINFLAMMATION
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17. Morphine induces loss of pericyte and influx of monocyte in vivo
Pericyte, important constituents of the cerebrovascular unit, play an essential role
in maintaining the integrity of the blood-brain barrier (Sweeney et al., 2016). Several
studies have demonstrated pericyte coverage is positively correlated with the integrity of
BBB (Daneman et al., 2010) and controlling the influx of immune cells (Bell et al., 2010;
Proebstl et al., 2012; Stark et al., 2013). Additionally, drugs of abuse such as opioids are
well recognized to result in a breach of the BBB, which, in turn, leading to an enhanced
influx of monocyte and ensuing neuroinflammation. The role of pericytes in morphinemediated neuroinflammation, however, remains less understood.
For this, we sought to examine whether morphine induces pericyte loss and influx
of monocyte. DesRed-NG2 pericyte mice (male, n=4) were administrated either saline or
morphine (an initial dose: 10 mg/kg) with intraperitoneal injection three times a day,
followed by ramping the dose by 5 mg/kg for another six days (Cai et al., 2016). On Day
6, mouse bone marrow-derived monocytes (BMMs) isolated from C57BL/6N mice followed
pre-labeling with Green CellTracker CMFDA. And the CMFDA-labeled BMMs were tail
vein injected to those DesRed-NG2 pericyte mice. After an additional 24 h, at the end of
morphine treatment, the mice were sacrificed within one hour. And the brain sections were
assessed for the distribution of CMFDA+ monocytes. As shown in figure 23A, we found a
significant increase in the number of CMFDA+ monocytes in the thalamus of mice
administrated morphine compared with the saline group. Intriguingly, we also found in the
brain of the morphine group showed less NG2+ positive pericyte compared with the saline
group, indicating the more loss of pericyte the more influx of monocyte in the context of
morphine administration. To further confirm morphine-induced loss of pericyte, the brain
sections from DesRed-NG2 pericyte mice (male, n=4) administrated either saline or
morphine for 7 days were stained with anti-CD31 (Endothelial cells marker), followed an
assessment of pericyte coverage around the endothelium. As shown in Figure 23B, there
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was a reduced ratio of NG2+pericyte/CD31+endothelia, indicating reduced pericyte
coverage in morphine-administrated mice compared with the saline mice. Next,
microvessels from C57BL/6N mice (male, n=4) administrated either saline or morphine for
7 days were also subjected to double immunostaining using antibodies specific for
PDGFR-β (another pericyte marker, green color) and CD31 (endothelial marker, red color)
for examining whether morphine can induce loss of pericyte ex vivo. As shown in Figure
23C, there was a reduced expression of the pericyte marker PDGFR-β in microvessels
isolated from morphine-administrated mice. Additionally, increased loss of pericyte loss
was further recapitulated in microvessels isolated from the brains of macaque
administrated with morphine (Figure 23C), further confirming that morphine exposure
could result in loss of pericyte coverage.
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Figure 23 Morphine induces influx of monocyte and loss of pericyte in vivo.
(A) Representative images of CMFDA-labeled monocyte and DesRed-NG2
pericyte in the thalamus of mice administrated saline or morphine. n = 4 per group. Arrow:
CMFDA-labeled monocyte (green color); bar, 20 µm; Quantification of CMFDA+ cells in
the thalamus. Two-tailed Student’s t-test (B) representative images of immunostaining of
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endothelial cell marker CD31 (green) in brain sections of DesRed-NG2 pericyte miceadministrated with saline or morphine. n = 4 per group; bar, 20 µm; Quantification of ratio
of NG2+ fluorescent intensities area/ CD31+ fluorescent intensities area.Two-tailed
Student’s t-test. (C) Representative images of double immunostaining of pericyte marker
PDGFR-β (Green) and endothelial cell marker CD31 (Red) in microvessels isolated from
either C57BL/N6 mice or Macaque administrated with saline or morphine; Quantification
of the ratio of PDGFR-β+ fluorescent intensities area/ CD31+ fluorescent intensities area.
Two-tailed Student’s t-test. All data are presented as mean ± SD,* P<0.05, ** P<0.01, ***
P<0.001 vs. saline group using Student’s t-test.
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18. Morphine-ADEVs induce migration of pericyte in vitro.
We are having demonstrated morphine mediated loss of pericyte in vivo. Next, we
sought to examine what is the mechanism by which morphine-induced pericyte loss. Other
studies and our previous study have demonstrated the migration of pericyte could be the
novel mechanism involved in the loss of pericyte (Niu et al., 2014; Pfister et al., 2008). For
this, we would like to test whether morphine induces the migration of pericyte. Exposure
of human primary pericyte to morphine (10 μM) for 24h, followed an assessment of
pericyte migration using transwell migration assay. As shown in Figure 24A, morphine can
not significantly induce pericyte migration. Intriguingly, in chapter III, we have
demonstrated that morphine can induce the expression of miR23a in the ADEVs. And a
lot of studies have demonstrated miR-23a could regulate cell migration (Huang et al., 2018;
Tian et al., 2015a; Xing et al., 2019). Additionally, several studies showed miR23 is highly
and exclusively expressed in astrocyte in the CNS (Brites and Fernandes, 2015; Gioia et
al., 2014; Smirnova et al., 2005; Wang et al., 2008). These pieces of information indicate
that ADEV-miR23a may result in the migration of pericyte.
Exposure of pericyte to either control- or morphine-ADEVs for 24hrs, followed an
assessment of pericyte migration using transwell migration assay. As the results showed
in Figure 24B, morphine-ADEVs significantly induced the migration of pericyte. Next, we
also performed the wound-healing migration assay to further confirmed morphine-ADEVs
do induce pericyte migration.
Since we have demonstrated morphine-ADEVs induced migration of pericyte., the
nest question is whether pericyte migration leads to pericyte loss coverage on the
endothelial cells. To answer this, we developed the pericyte-endothelial cells co-culture
model to assess the loss of pericyte in vitro. The pericyte exposed to either control- or
morphine-ADEVs for 24hrs, followed labeling pericyte with cell tracker CMFDA (green) as
well as labeling HBMECs with cell tracker CMTPX (Red). The cell tracker labeled Pericyte
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and HBMECs were mix at the ratio 1:4 (pericyte: HBECs), followed by seeding these
mixed cells onto the matrix gel for co-culture 24hrs. Then to check the pericyte coverage
ratio on the HBMEC under the confocal microscopy. As shown in Figure 24C, HBMEC
(red) formed the tube structure and pericyte (Green) attached to the HBMEC, there was a
significant decrease of pericyte-exposed to morphine-ADEVs on the HBMEC compared
with the pericyte-exposed to control-ADEVs. This data indicated that morphine-ADEVs
could induce pericyte loss coverage in vitro.
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Figure 24 Morphine-ADEVs induce pericyte migration and loss in vitro.
(A & B) The migration of pericyte was measured by transwell migration assay.
The representative images of migratory pericyte stained by crystal violet. Scale bar
= 20 µm, morphine can not induce migration of pericyte (A); morphine ADEVs induce
migration of pericyte (B). (C) Migration of pericyte was measured by the wound-
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healing assay. The representative images of pericyte stained by crystal violet and
then analyzed by Image J software. Scale bars, 100 μm. (D) Loss of pericyte was
measured by a 3D pericyte (green)-endothelia (Red) co-culture model, and then the
representative images analyzed by Image J. Scale bars, 50 μm. All data are
presented as mean ± SD, * P<0.05, *** P<0.01 vs control group using one-Way
ANOVA analysis.
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19. Morphine-ADEVs induce migration of pericyte involves in transporting miR23a
from astrocyte to pericyte.
In chapter III, we have shown exposure of astrocyte to morphine resulted in the
upregulation of miR23a in the ADEVs, which is the miRNA reported to regulate cellular
migration. We first validated morphine can time-dependently induce expression of miR23a
in ADEVs (Figure 25A), and next, we are wondering whether morphine induces upregulation of miR23a in the astrocyte. To answer this, astrocytes were exposed to
morphine for 24 hrs, followed an assessment of pre-and mature-miR23a expression in the
astrocyte using real-time PCR. As shown in Figure 25B and 25C, morphine significantly
induced the upregulation of pre- and mature-miR23a in astrocyte. Additionally, we also
validated the upregulation of miR-23a in the basal ganglia isolated from the control and
morphine administration macaques using the real-time PCR. As shown in figure 25D,
there was an increased expression of miR23a in the basal ganglia of morphine-dependent
macaques compared with the untreated control group. Furthermore, we validated these
findings by in situ hybridization, the increased expression of miR-23a in the GFAP+
astrocytes in the brains of morphine-dependent macaques (Figure 25E) compared
untreated controls.
Then, we investigated whether morphine-exposed ADEVs containing miR-23a
could be transferred from astrocytes into pericytes, which, in turn, leading to the migration
of recipient cells. Under basal conditions, as shown in figure 25B and 25C, pericytes
express a much lower level of pre- and mature-miR23a amount compared with astrocyte.
Additionally, exposure of pericyte to morphine did not increase miR-23a transcription (premiR-23a levels) or the levels of mature miR-23a in pericytes (Figure 25B and 25C).
Intriguingly, we co-cultured pericyte and astrocyte in the transwell system. Astrocytes were
seeded in the transwell (on top) and exposed to morphine for 24 hrs, followed by coculturing with pericyte (on bottom) for the other 24 hrs. Then to harvest pericytes for RNA
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extracting, followed by an assessment of pre- and mature-miR23a using real-time. As
shown in figure 25F, in the co-culture system, morphine-exposed astrocyte increased
mature-miR23a, but not pre-miR23a in pericyte, indicating morphine-exposed ADEVs
containing miR-23a transferred from astrocytes into pericytes that leads to upregulation of
miR23a in pericyte. Further, astrocytes were pre-transfected with the plasmid of mCherryTSG101 for 24hrs and seeded into the top transwell for co-culturing with pericyte for
another 24 hrs, followed fixing pericyte with 4% PFA and then the pericyte immunostained
with PDGFR-β (Green). As shown in figure 25G, we can detect the red signal of mCherryTSG101-labeled ADEVs in PDGFR-β + pericyte, indicating that pericyte could take up
ADEVs released from astrocyte.
Furthermore, we sought to confirm the Morphine-ADEVs-induced migration of
pericyte involves in ADEV-miR23a. Pericytes were pre-transfected with the inhibitor of
miR23a for 24 hrs, followed by exposure of pericyte to either control- or morphine-ADEVs
for 24hrs, followed by an assessment of pericyte migration using transwell migration assay
(Figure 26A), wound-healing assay (Figure 26B) and 3D pericyte-endothelial cells
coculture model (Figure 26C). As the results showed in Figure 26, morphine-ADEVs
significantly induced the migration of pericyte. However, in the group of miR23a inhibitortransfected pericyte morphine-ADEVs failed to induce migration of pericyte assessed by
transwell migration assay (Figure 26A), wound-healing assay (Figure 26B) and 3D
pericyte-endothelial cells coculture model (Figure 26C).
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Figure 25 Morphine-ADVEs induced the upregulation of miR23a in pericyte via ADEVsmediated transporting miR23a from astrocyte to pericyte.
(A) ADEVs isolated from astrocytes either treated with or without morphine
for indicated time points, followed by an assessment of miR23a expression using
RT-PCR. (B and C) Either pericyte of astrocyte treated with or without morphine for
24 hrs, followed by an assessment of pre- (B) or mature-miR23a (C) expression
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using RT-PCR. (D and E) miR-23a is upregulated in the brains of morphinedependent macaques as assessed by (D) q-PCR and, (E) in situ hybridization. (F)
Exposure of astrocyte to morphine for 24 hrs, followed by co-culturing with pericyte
for another 24hrs. Then extracted RNA form pericyte, followed by and assessment
of pre- or mature-miR23a in the pericyte. (G) mCherry TSG101-transfected mouse
primary astrocytes for 24 hrs, followed by coculturing with pericyte for another 24.
Paraformaldehyde fixed pericyte cells were permeabilized and stained for pericyte
marker PDGFR-β (Green) and visualized by fluorescence microscopy. Scale bars,
20 μm. All data are presented as mean ± SD, * P<0.05, ** P<0.01, *** P<0.001 vs.
control group using one-Way ANOVA analysis.
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Figure 26 Morphine-ADVEs induced the migration of pericyte involved ADEVs-miR23a.
(A) The migration of pericyte was measured by the wound-healing assay. The
representative images of pericyte stained by crystal violet and then analyzed by Image J
software. Scale bars, 100 μm. (B) The migration of pericyte was measured by transwell
migration assay. The representative images of migratory pericyte stained by crystal violet.
Scale bar = 100 µm. (C) Loss of pericyte was measured by a 3D pericyte (green)endothelia (Red) co-culture model, and then the representative images analyzed by Image
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J. Scale bars, 50 μm. All data are presented as mean ± SD, * P<0.05, *** P<0.01 vs control
group, # P<0.05 vs morphine-ADEVs group using one-Way ANOVA analysis.
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20. The mechanism by which morphine induces upregulation of

miR23a in

ADEVs.
It is well known that morphine is a mu receptor (one of the opioid receptors )
agonist. Next, we sought to examine whether morphine-mediated induction of miR-23a
either in astrocytes or ADEVs involved in the mu receptor. For this, astrocytes were
pretreated with the opioid receptor antagonist naltrexone (10 μM) (Mohan et al., 2010; Yue
et al., 2008) one hour prior to morphine treatment, followed by extracting RNA from
astrocytes as well as isolating ADEVs from the culturing media. As shown in figure 27A,
pre-exposure of astrocyte with naltrexone significantly abrogated morphine-induced
upregulation of miR23a in the astrocyte as well as in the ADEVs (Figure 27B).
Next, we would like to examine what is the mechanism by which morphinemediated sorting of miR-23a into the ADEVs. Villarroya-Beltri et al. did the study that has
demonstrated

the

mechanism

by

which

SUMOylated

heterogeneous

nuclear

ribonucleoprotein A2/B1 (hnRNP A2/B1)-mediated sorting of miRNAs into EVs (VillarroyaBeltri et al., 2013). They summarized several specific motifs present in some miRNAs that
could be the target of hnRNP A2/B1 for binding, sequentially its binding will facilitate the
sorting of these miRNAs in the EVs. Intriguingly, we also find the hnRNP A2/B1 binding
motif within the miR23a. Thus, we sought to explore whether morphine-mediated
upregulation of miR23a involved in hnRNP A2/B1. First of all, we observed a timedependently increase in the level of hnRNP A2/B1 protein in the astrocyte as well as the
ADEVs released from astrocytes exposed to morphine (Figure. 27C). Next, the astrocytes
were transfected with either si-control or si-hnRNP A2/B1 for 24 hrs, followed by
astrocytes exposed to morphine for another 24 hrs. As shown in figure 27D, si-hnRNP
A2/B1 successfully knocked down the expression of hnRNP A2/B1 in the astrocyte.
Additionally, in the hnRNP A2/B1 knocking down group, morphine failed to induce the
upregulation of hnRNP A2/B1 in the astrocytes as well as ADEVs (Figure 27E). Meanwhile,
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we also extracted RNA from these astrocytes as well as ADEVs. Interestingly, we found
morphine induces the upregulation of intracellular miR-23a no matter hnRNP A2/B1
knocking down or not (Figure 27F). However, morphine failed to induce the upregulation
of miR-23a in the ADEVs (Figure 27B). These findings implicated morphine-mediated the
upregulation of miR23a in the ADEVs involved in hnRNP A2/B1-mediated sorting of
miR23a into the ADEVs.
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Figure 27 Morphine-mediated the upregulation of miR23a in the ADEVs involved mu
receptor and hnRNP A2/B1.
(A,B) Astrocytes pretreated with naltrexone (10 μM) for 1 h, followed by 24 hrs
exposure of morphine. The expression of miR23 in astrocytes (A) and ADEVs (B) was
assessed using real-time PCR. Each set of results were quantified upon three
independent experiments. All data are presented as mean ± SD, * P<0.05, ** P<0.01 vs
control group; # P<0.05, ## P<0.01 vs morphine group using one-Way ANOVA analysis.
(C) Representative western blot image of hnRNP A2/B1 expression in the lysates from 24
hrs morphine-treated astrocyte and ADEVs. (D, E) Representative western blot image of
hnRNP A2/B1 expression in the lysates from astrocytes (D) or ADEVs (E) with or without
hnRNP A2/B1 knockdown treated with or without morphine. Each set of results were
quantified upon three independent experiments. All data are presented as mean ± SD, *
P<0.05, *** P<0.001 vs si-ctl-control group; # P<0.05, ## P<0.01 vs si-ctl-morphine group
using one-Way ANOVA analysis. (F, G) Astrocytes transfected with either si-ctl or sihnRNP A2/B for 24 hrs, followed by 24 hrs exposure of morphine. The expression of
miR23 in astrocytes (F) and ADEVs (G) was assessed using real-time PCR. Each set of
results were quantified upon three independent experiments. All data are presented as
mean ± SD, * P<0.05, ** P<0.01 vs si-ctl-control group; # P<0.05, ## P<0.01 vs si-ctlmorphine group using one-Way ANOVA analysis.
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21. ADEVs-MiR-23a targets PTEN in pericyte.
Having demonstrated the mechanism by which morphine induced upregulation of
miR23a in ADEVs. Sequentially, ADEVs-miR23a were taken up by pericyte that results in
the migration of pericyte. Now, we are thinking about what is the downstream target of
miR23a in pericytes. According to bioinformatics studies, PTEN has been shown to be a
target of miR23a (Han et al., 2017; Wang et al., 2018). Additionally, PTEN has been shown
to inhibit AKT pathway, which, in turn, leading to regulate cellular migration (Tian et al.,
2015a) negatively. Thus we sought to examine whether ADEV-miR-23a mediated
migration of pericyte involved downstream of miR-23a targeting PTEN in recipient pericyte.
Having determined the ADEVs containing miR-23a can be taken up by pericyte,
subsequently transferring miR-23a from astrocyte to pericyte. Thus ADVE-miR23 could
bind directly to the 3′-untranslated region (3’UTR) of the PTEN mRNA, achieving inhibition
of its translation. First of all, we sought to validate PTEN as a target of miR23a in our
system. If HEK293 cells were transfected with a PTEN-3’UTR luciferase reporter construct,
a miR23a potential binding element in PTEN 3’UTR could regulate the expression of
luciferase in HEK293 cells. Here, we co-transfected HEK293 cells with both miR-23a
mimic and PTEN-3’UTR-luciferase constructs. As shown in figure 28A, miR-23a mimic
resulted in a significant decrease in luciferase activity, indicating thereby PTEN is a target
of miR23a. As a negative control, we also co-transfected HEK293 cells with both miR23a
mimic and a construct with a mutation in the miR-23a-binding region of the PTEN 3’UTR.
As expected, miR-23a mimic failed to reduce luciferase activity in the group of the cells
transfected with the PTEN 3’UTR mutant (Figure 28A). Further confirmation of the role of
ADEV-miR-23a in regulating PTEN translation was carried out by transfecting pericyte
with an inhibitor of miR-23a, followed by exposure of pericyte to either control-ADEV or
morphine-ADEV and subsequently assessing the expression of PTEN protein by western
blot. As shown in Figure 28B-D, morphine-ADEVs significantly reduced the expression of
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PTEN protein compared with cells exposed to control-ADEVs. However, morphine-ADEVs
failed to decrease the expression of PTEN in the group of the cells transfected with the
inhibitor of miR23a, indicating morphine-ADEVs-mediated down-regulation of PTEN
involved ADVE-miR23a. Interestingly, we also found, morphine-ADEVs activated AKT
pathway via inducing phosphorylation of AKT. However, in the cells transfected with the
inhibitor of miR23a, morphine-ADEVs failed to activate the AKT pathway.
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Figure 28 ADEVs-miR23a targets PTEN that leads to activation of the AKT pathway.
(A) Putative miR-23a binding site in PTEN mRNA. Relative luciferase activity of
WT or 3′UTR mutant constructs of PTEN in HEK293 cells co-transfected with miR-control
or miR-23a mimic. All data are presented as mean ± SD, * P<0.05, *** P<0.01 vs control
group using one-Way ANOVA analysis. (B) Representative western blot and (C, D)
quantification of PTEN (C), AKT and p-AKT (D) protein levels in pericytes transfected
either with control-miR or miR-23a mimics for 24 hrs, followed by treatment of ctl-ADEVs
or morphine-ADEVs. Each set of results were quantified upon three independent
experiments. All data are presented as mean ± SD, * P<0.05, *** P<0.001 vs ctl-ADVs
group; # P<0.05 vs morphine-ADEVs group using one-Way ANOVA analysis.
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22. Morphine-ADEVs-mediated

migration

of

pericyte

involved

in

the

miR23a/PTEN/AKT axis.
To further confirm that whether PTEN as a key player in ADEVs-miR23a-mediated
migration of pericyte. Pericytes were transfected with either Flag-PTEN overexpression
construct lacking the UTRs (therefore no miR23a targeting), or a control vector, followed
by exposure to ctl-ADEVs or morphine-ADEVs. Migration of pericyte was assessed using
a transwell migration assay (figure 29A), wound healing assay (figure 29B) and 3D
pericyte-endothelia co-culture model (figure 29C). As shown in Figures 29, morphineADEVs failed to induce migration of pericyte in the group of pericyte transfected with FlagPTEN.
In keeping with these findings, we further transfected either miR23a-PTEN target
protector oligo (miR23a-PTEN-TP) in pericyte that specifically protected the miR-23a
binding site on the endogenous PTEN 3’UTR or a scrambled target protector oligo,
followed by exposure of pericyte to ctl-ADEVs or morphine-ADEVs. Migration of pericyte
was assessed using a transwell migration assay (figure 30A), wound healing assay (figure
30B) and 3D pericyte-endothelia co-culture model (figure 30C). As shown in Figures 30,
in the presence of miR23a-PTEN-TP, morphine-ADEVs failed to induce migration of
pericyte. Therefore, our finding further confirmed that PTEN plays an essential role in
morphine-ADEVs-mediated pericyte migration.
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Figure 29 Overexpression of PTEN attenuates morphine-ADEVs-mediated migration of
pericyte.
(A,B,C) Pericytes were transfected with either vector or PTEN overexpression
plasmid (PTEN OE) for 24 hrs, followed by exposure to either Ctl-ADEVs or morphine
ADEVs. Then the migration of pericyte was measured by transwell migration assay (A).
The representative images of migratory pericyte stained by crystal violet. Scale bar = 100

130
µm. The migration of pericyte was measured by the wound-healing assay (B). The
representative images of pericyte stained by crystal violet and then analyzed by Image J
software. Scale bars, 100 μm. Loss of pericyte was measured by 3D pericyte (green)endothelia (Red) co-culture model (C), and then the representative images analyzed by
Image J. Scale bars, 50 μm. All data are presented as mean ± SD, * P<0.05, *** P<0.01
vs control group (Vector-CTL-ADEVs), # P<0.05, ## P <0.01 vs Vector-morphine-ADEVs
group using one-Way ANOVA analysis.
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Figure 30 miR-23a-PTEN-TP attenuates morphine-ADEVs-mediated migration of pericyte.
(A,B,C) Pericytes were transfected with either oligo of target protector control
(CTL-TP) or miR23a-PTEN-target protector (miR23a-PTEN-TP) 24 hrs, followed by
exposure to either Ctl-ADEVs or morphine ADEVs. Then the migration of pericyte was
measured by transwell migration assay (A). The representative images of migratory
pericyte stained by crystal violet. Scale bar = 100 µm. The migration of pericyte was
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measured by the wound-healing assay (B). The representative images of pericyte stained
by crystal violet and then analyzed by Image J software. Scale bars, 100 μm. Loss of
pericyte was measured by 3D pericyte (green)-endothelia (Red) co-culture model (C), and
then the representative images analyzed by Image J. Scale bars, 50 μm. All data are
presented as mean ± SD, * P<0.05, *** P<0.01 vs control group (CTL-TP-CTL-ADEVs), #
P<0.05, ## P <0.01 vs CTL-TP-morphine-ADEVs group using one-Way ANOVA analysis.
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23. Disscusion
It is well known that morphine abuse closely linked with HIV infection (El-Hage et
al., 2015; Reynolds et al., 2012; Vaidya et al., 2016; Wang and Ho, 2011). A lot of studies
have demonstrated morphine doesn’t only potentiate the progression of HIV infection but
also exacerbate the neurological complications associated with the disease. Morphine has
a detrimental effect on most CNS cells, such as the endothelium (Lam et al., 2007),
astrocytes (Sil et al., 2018; Stiene-Martin et al., 1991), microglia (Bokhari et al., 2009; Ryu
et al., 2018) and neurons (Smith et al., 2012), likely contributing to the pathogenesis of
HIV-associated neurocognitive impairment. In our current studies, we have demonstrated
another novel role of pericytes in a morphine-mediated increased influx of monocyte into
the CNS. Here, we demonstrate a novel molecular mechanism underlying morphinemediated induction of miR23a in ADEVs, taken up by the pericyte resulting down
regulation of PTEN, which, in turn, leading to migration of pericyte and thus to enhance
influx of monocyte.
Recently, pericyte is considered as a key player in maintaining the integrity of the
blood-brain barrier. Several studies have demonstrated pericyte coverage is positively
correlated with the integrity of BBB (Bell et al., 2010; Proebstl et al., 2012; Stark et al.,
2013), demonstrating the more loss of pericyte coverage on the vessels the more influx of
immune cells. Drugs of abuse such as opioids are well recognized to result in a breach of
the BBB, which, in turn, leading to an enhanced influx of monocyte and ensuing
neuroinflammation. The role of pericytes in morphine-mediated neuroinflammation,
however, remains less understood. Here, our in vivo studies first time to show Morphinemediated loss of pericyte on the brain vessels, further promoting the influx of monocytes.
Furthermore, we also confirmed these findings in our ex vivo studies, wherein the
reduction in expression of PDGFR-β pericytes in microvessels isolated from either mice
or macaques administrated with morphine.
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Emerging evidence demonstrated that miRNAs as key regulators in almost every
cellular process. Generally, miRs control gene expression at the post-transcription level
through regulating degradation or translational repression of target mRNAs (Catalanotto
et al., 2016). In our current studies, to our knowledge we are the first time to demonstrated
morphine-mediated dysregulation of miR expression in the astrocytes involves cellular
crosstalk with the pericytes via the ADEVs, leading to migration of pericyte, which in turn
could lead to reduced pericyte coverage with an increased influx of monocyte-associated
neuroinflammation observed in HANDs. We observed exposure of astrocytes to the
morphine resulted in the upregulation and release of miR-23a in the ADEVs that is the
mu-receptor dependent. This is in agreement with previous studies (Hwang et al., 2012;
Toyama et al., 2017), demonstrating miRNA-23a is an opioids-receptor regulating miRs.
Furthermore, we have demonstrated the mechanism by which morphine-mediated an
increase expression of ADEV-miR23a via hnRNP A2/B1-mediated sorting of miRNA-23a
into the ADEVs. The RNA binding protein hnRNP A2/B1 has been reported to play a role
in the sorting of miRNAs into the EVs. For example, Villarroya-Beltri et al. did the study
that has demonstrated the mechanism by which SUMOylated hnRNP A2/B1-mediated is
sorting of miRNAs into EVs via binding to the exosomal-sorting motif (Villarroya-Beltri et
al., 2013). Interestingly, we also find the hnRNP A2/B1 binding motif within the miR-23a.
Additionally, we have discovered the exposure of astrocyte to morphine resulted in timedependently upregulation of hnRNP A2/B2 in astrocytes as well as ADEVs. Here, we
showed that knockdown of hnRNP A2/B1 attenuates morphine-mediated upregulation of
miR23a in the ADEVs as well as the migration of pericyte. According to our findings,
hnRNP A2/B1 could potentially contribute to downstream pathology such as inducing
migration of pericyte via regulating levels of ADEVs-miR23a. Therefore, in astrocyte
hnRNP A2/B1 could be the novel target to an attenuated morphine-mediated loss of
pericyte associated neuroinflammation.
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PTEN, as a tumor suppressor, was well studied in the field of cancer studies
(Tamura et al., 1999). Loss or mutation of PTEN has been observed in ∼45% of
endometrial cancers, ∼30% of glioblastomas (Tamura et al., 1999). In an other number of
cancers, the PTEN is also at lower expression levels, such as prostate cancer,
glioblastoma, lung, and breast cancer (DeGraffenried et al., 2004; Zhu et al., 2013). The
depletion of PTEN results in the phosphorylation of FAK (Tamura et al., 1999) as well as
activation of the Akt/PKB pathway (Chin and Toker, 2009), which, in turn, leading to the
promotion of cell invasion, migration, and growth. Intriguingly, Lin Zhang et al. were the
first group to show astrocyte-derived exosomal miR-19a-mediated loss of PTEN
expression in cancers cell, which, in turn, leading to the promotion of brain metastasis
(Zhang et al., 2015a). Additionally, our previous study also demonstrated astrocytederived EV-miR9-mediated reduction of PTEN expression that promoted microglial
migration in the context of HIV Tat stimulation. In our current study, we have found that
exposure of astrocyte to morphine resulted in the upregulation of ADEV-miR23a that can
be taken up by the pericyte, targeting PTEN, which, in turn, leading to migration of pericyte.
Herein, we were the first time to demonstrate that EV-miR-23-induced downregulation of
PTEN expression enhanced pericyte migration. Intriguingly, we also showed that
transfected pericyte with miR-23a-PTEN-TP or plasmid of PTEN overexpression that
could attenuate morphine-ADEVs-mediated pericyte migration. Therefore, in pericyte
PTEN could be the novel target to an attenuated morphine-mediated loss of pericyte
associated with neuroinflammation.
In summary, our findings demonstrate a novel mechanism by which morphinemediated migration of pericyte resulted in pericyte loss and influx of monocyte in vivo,
involving the release of ADEV-miRNA-23a and uptake of ADEVs by pericyte and
activation of PTEN/Akt pathway. These findings have implications for heroin abusers that
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are known to have increased risk of neuroinflammation, which, in turn, contributing to
developing HAND.
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CHAPTER VI
SUMMARY
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Opioids, such as morphine, are widely used prescription analgesics for acute
postoperative pain and other moderate to severe pain in the emergency department and
primary care settings(Casamayor et al., 2018; Haroutounian, 2018). In 2017, there are
total 191 million opioids prescriptions, with the rate of 58.7 prescriptions 100 people (CDC,
2018). It has been shown that even patients who undergo short-stay surgery are at
increased risk of long term opioids use after received opioid prescriptions (Alam et al.,
2012). From 2007 to 2017, drug overdose deaths involving any opioid has increased 2.6
fold, from 18,515 to 47, 600 (NIH, 2019). The opioids usage was found to cause the
severity of central nervous system (CNS) disease, including memory disorders,
depression (Sullivan, 2018; Terrett et al., 2014). It has also been reported that morphine
accelerating HIV infection and HIV-associated neuroinflammation (Dave, 2012; El-Hage
et al., 2015; Li et al., 2003; Reddy et al., 2012), while the mechanisms underlying
morphine-associated CNS disease progression and pathogenesis remains largely
unknown. Neuroinflammation, an inflammatory response within nervous tissue, is
triggered by a variety of endogenous and exogenous sources, such as invading pathogens,
toxic molecules, and neuronal injury. It is characterized by the activation of glial cells, the
release of inflammatory molecules, the disruption of the blood-brain barrier, and the influx
of peripheral immune cells into the brain. In this thesis, we focus on the mechanism(s) by
which morphine-induced neuroinflammation via regulating microglial function and BBB
function.
Extracellular vesicles (EVs) play an important role in cell-to-cell communication
since various proteins, lipids and RNAs that are specifically incorporated into these
vesicles, can be targeted to remote cells through receptor-ligand interactions(Russell et
al., 2019; Sun et al., 2018b; Tkach and Thery, 2016). Recently, the interest in exploring
the source and features of EVs generates in various pathologies as EVs represent a
potential source for biomarker discovery, including cancer(Eylem et al., 2019; Joyce et al.,
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2016; Lewis et al., 2018; Liu et al., 2018), CNS diseases (Gamez-Valero et al., 2019; Shi
et al., 2014), and viral infections(Liu et al., 2019; Rodrigues et al., 2018; Shen et al., 2017).
In CNS, EVs were found released by most of cell types and have been associated with
numerous neurodegeneration diseases, including Alzheimer Disease (Sardar Sinha et al.,
2018), Parkinson’s disease (Shi et al., 2014), Amyotrophic Lateral Sclerosis(Roy et al.,
2019) and HIV-associated neurocognitive diseases(Sampey et al., 2016; Yang et al.,
2018). MiRNAs, the small, evolutionarily conserved noncoding RNAs, have been
demonstrated as main regulator in EV-mediated cell communications in CNS, and
contribute to the progression of various neurocognitive disease (Gupta and Pulliam, 2014;
Men et al., 2019; Selmaj et al., 2017; Xia et al., 2019). In our previous study, we reported
that miR-9 released from Tat-stimulated astrocytes could be taken up by microglia,
resulted in enhanced microglial migration via regulating PTEN expression. This study
provided evidence of crosstalk between glial cells via EVs-miR9 which play a critical role
in HIV-associated neurocognitive disorders (Yang et al., 2018). In addition to the virus
factor, drugs of abuse such as opioids or cocaine can also dysregulate the expression of
miRNAs. An interesting study by Dave & Khalili showed that morphine-induced
inflammation & oxidative stress in human monocyte-derived macrophages contributed to
the expansion of the HIV-1 viral reservoir in the CNS and HIV-associated dementia(Dave,
2012). The authors provided evidence that this process was regulated by differentially
expressed miRNAs, including miR-15b & miR-181b, both linked to several targets in the
proinflammatory pathways. Similarly, findings from our lab have reported that exosomemediated shuttling of miR-29b regulates HIV Tat and morphine-mediated neuronal
dysfunction (Hu et al., 2012). Another interesting effect associated with miRNAs derives
from their capacity to activate receptors, after being secreted by cells, which allows them
to function as signaling molecules. For example, let-7 is known to induce
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neurodegeneration by binding to TLR7 receptor in neurons and microglia (Lehmann et al.,
2012).
In line with these findings, our thesis data first time to demonstrate EVs derived
from astrocytes exposed to morphine which been taken up by microglia and activated the
Toll-like receptor 7 (TLR-7) with subsequent upregulation of lincRNA-Cox2 expression,
ultimately resulting in impaired microglial phagocytosis (Yang et al., 2018). Importantly,
we also successfully develop a therapeutic strategy of delivering lincRNA-COX2-siRNA
via ADEVs to knock down lincRNA-Cox2 that achieve restoring morphine-impaired
phagocytic activity in microglia in vivo. Our findings have ramifications for the development
of EV-loaded RNA drug target(s) as therapeutics for a multitude of CNS disorders
involving microglial deficits associated with opiate abuse-mediated neuroinflammation.
Furthermore, we demonstrate that morphine induces the up-regulation of miR-138
in morphine-stimulated astrocyte-derived EVs (morphine-ADEVs), which can be taken up
by microglial cells, leading, in turn, activates the TLR7--NF-kB axis and contributes to
microglial activation. The upregulation of miR-138 is also confirmed in the basal ganglia
in the brains of morphine-dependent rhesus macaques. Additional, we demonstrate that
intranasal delivery of miR-138 inhibitor can restore microglial activation induced by
morphine-ADEVs. In chapter III and IV, we demonstrate a novel mechanism by which
morphine-mediated dysregulation of microglia via ADEV-miRNAs biding with TLR7 in the
recipient microglial cells, triggering downstream signaling pathway that ultimately induces
inhibition of microglial phagocytosis and activation of microglia. Besides that, we also have
to mention miRNA-cargo also can regulate cellular function via miRNA-mRNA interaction
in the recipient cells. Future IPA bioinformatic analysis is needed to understand the
complex regulatory networks in the context of morphine-ADEVs-mediated the
dysregulation of miRNAs.
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In terms of ADEV-miRNA-cargo regulating cellular function via miRNA-mRNA
interaction in the recipient cells, our current study in chapter V demonstrates a novel
mechanism by which morphine-induced the expression and secretion of miR-23 in the
ADEVs, which, upon uptake by pericytes, resulted in downregulation of PTEN that
promoting pericyte migration. Additionally, we also showed that transfected pericyte with
miR-23a-PTEN-TP or plasmid of PTEN overexpression that could attenuate morphineADEVs-mediated pericyte migration. Therefore, delivery of EV-loaded miR-23a-PTEN-TP
or PTEN-lentivirus into the brain could be the therapeutics to attenuated morphinemediated loss of pericyte associated with neuroinflammation.
Thus our results strongly support ADEVs play an essential role in morphinemediated neuroinflammation via regulating microglia and pericyte function (Figure 1).
Furthermore, based on our findings, we have ramifications for the development of EVloaded RNA-based therapeutics for the treatment of various disorders involving functional
impairment of microglia and pericytes.
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